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Abstract 
Ventilator associated pneumonia (VAP) is a significant challenge for the Intensive Care 
doctors worldwide.  It is both difficult to diagnose accurately and quickly and to treat 
effectively once the diagnosis has been established.  Current diagnostic microbiological 
methods of diagnosis can take up to 48 hours to yield results.  Early diagnosis and 
treatment remain the best way of improving outcome for patients with VAP. 
 
In this study we look at novel diagnostic techniques for VAP.   Electronic nose (Enose) 
technology was used to identify to identify the presence of microorganisms in 
bronchoalveolar lavage (BAL) fluid samples taken from the respiratory tracts of 
ventilated patients.  The results were compared with standard microbiological culture and 
sensitivities. The Enose was able to discriminate 83% of samples into growth or no 
growth groups on samples grown in the lab.  When the technique was employed to 
samples taken directly from patients the accuracy fell to 68.2%.  This suggests that 
patient related factors may be reducing the accuracy of the Enose classification.  The use 
of antimicrobial drugs prior to patient sampling is likely to have played a major role. 
 
The second part of this study used Gas Chromatography-Mass Spectrometry (GC-MS) 
analysis of patient‟s breath in an attempt to identify patients with VAP.  Breath samples 
were taken at the same time as the bronchoalveolar lavage samples described above.  The 
use of this technique did show differences between the breath samples of patients who 
did not have any microbiological growth from their BAL samples and those that did. 
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Leave one out cross validation of a PC fed LDA model showed 84% correct classification 
between healthy volunteers, no growth and growth groups. 
 
Finally, we evaluated the Breathotron, which is a breath analysis device designed and 
built at Cranfield Health.  It allows for analysis of breath samples using a single sensor 
system as opposed to a sensor array employed in traditional Enose devices.  This allows it 
to be more portable and cheaper to build.  The Breathotron also allows collection of 
breath onto sorbent cartridges for GC-MS analysis.  Its single sensor did not allow for 
accurate discrimination between samples. 
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1.1 Introduction 
“Hospital acquired pneumonia (HAP) is an infection of the lungs, usually due to 
bacterial, viral or fungal pathogens, that is defined as occurring more than 48 hours after 
admission to hospital”[1].  In the USA, HAP is the second most common hospital-
acquired infection but leads to the greatest number of nosocomial-related deaths[1].  Over 
and above increased morbidity and mortality, HAP also results in extended hospital stays 
and is frequently managed with prolonged antibiotic treatment, resulting in additional 
financial burdens and antibiotic resistance in hospitals.  Favourable outcomes centre on 
the prevention of HAP when possible and the prompt use of appropriate antibiotics in the 
presence of infection[2]. This can be challenging when the aetiology of HAP is unknown. 
 
Since the 1970‟s the potential of breath analysis as a way of detecting disease in the 
human body has been recognised.  These early studies were primarily performed using 
GC-MS. In 1971 Pauling et al.[3] demonstrated that several hundred compounds were 
present in human breath and that some of these could be associated with abnormal 
physiological states or disease.   
 
When considering breath analysis, diseases of the lung and respiratory tract are the 
obvious choice for pathologies to be investigated as the vast majority of expired breath 
gas has been produced in the lung.  A small proportion will be dead-space gas, some of 
which may have come from the upper gastrointestinal tract. 
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All the methods for breath analysis rely on the detection of volatile organic compounds or 
VOCs. Organic compounds are those which contain carbon and are found in all living 
things.  VOCs are organic compounds that easily become gases or vapours; as such they 
can be detected in breath and bodily fluids.  Many studies, including those using GC-MS 
(Gas Chromatography-Mass Spectrometry) have shown that for certain pathological 
conditions (infection, malignancy, liver and cardiopulmonary disease) specific patterns of 
VOCs can be detected.  These patterns are known as “Volatile Fingerprints”.  It is hoped 
that these fingerprints will provide the basis for accurate breath screening for disease in 
the future. Although we have so far discussed using various technologies to analyse 
breath, these same technologies can also be employed to smell the headspace above 
bodily fluids such as blood and urine.  This adds another potential medical application to 
the uses of the technologies we have looked at so far. 
 
1.2 Research Objectives 
As can be seen from the literature review there has been extensive research into the 
application of various technologies for volatile detection in the field of medicine.  VAP is 
an obvious area for the application of this technology, which to this point in time has only 
been explored on a superficial basis.  The fact that early diagnosis and treatment of VAP 
improves outcome and that Enose technology in particular offers the ability to perform 
rapid, near patient diagnosis make the application of this technology to this important 
clinical problem an exciting prospect. 
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There are two distinct sections to this piece of work, which examine the use of Enose 
technology and GC-MS in the diagnosis of VAP: 
 
The diagnosis of VAP using Enose analysis of BAL fluid: 
In this section we compare the detection of infection in BAL fluid by Enose analysis with 
accepted microbiological culture and sensitivities. 
 
The diagnosis of VAP by using GC-MS analysis of exhaled breath from ventilated 
patient: 
In this section we look at the breath profiles from patients who have a positive BAL 
culture and compare them with breath profiles from patients who do not.  We hope to be 
able to detect the presence of compounds in the breath which may act as a “volatile 
fingerprint” for the presence of microbiological growth. 
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    Ventilator Associated Pneumonia 
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2.1 Introduction 
Ventilator associated pneumonia (VAP), one form of HAP, specifically refers to 
pneumonia developing in a mechanically ventilated patient more than 48 hours following 
endotracheal intubation[2].  Although not included in this definition, some patients may 
require intubation after developing severe HAP and should be managed in the same way 
as those with VAP. 
 
“There are approximately 300,000 cases of HAP and VAP annually in the USA, 
representing approximately 5-10 cases per 1,000 hospital admissions”[1].  Based on data 
from over 14,000 intensive care patients in the USA, HAP and VAP represent the second 
most common nosocomial infection, affecting 27% of all critically ill patients[4].  HAP 
accounts for up to 25% of all intensive care unit infections and more than 50% of all 
antibiotic use[4].  VAP occurs in 9-27% of all intubated patients[2, 5].  Among intensive 
care patients, nearly 90% of episodes of HAP occur during mechanical ventilation. 
 
In mechanically ventilated patients the incidence of VAP increases with the duration of 
ventilation. The risk of VAP is highest early in the course of hospital stay and is 
estimated to be 3% per day during the first 5 days of ventilation, 2% per day during days 
5-10 of ventilation and 1% per day after this[6]. Since most mechanical ventilation is 
short term, approximately half of all episodes of VAP occur within the first four days of 
mechanical ventilation. 
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In patients with respiratory failure, VAP is the primary cause of hospital acquired 
mortality.  HAP is associated with approximately 60% of all deaths in patients with 
nosocomial infections[7], and the mortality rate is increased in critically ill patients and 
those patients developing VAP. 
 
2.2 Pathophysiology of VAP 
Nosocomial pneumonia (of which VAP is a type) can occur by four routes: 
 
1. Haematogenous spread from a distant focus of infection 
2. Contiguous spread  
3. Inhalation of infectious aerosols  
4. Aspiration 
 
By far the most important cause is aspiration of the pathogenic Gram-positive and Gram-
negative bacteria that colonise the oropharynx and gastrointestinal tract.  The other routes 
of infection are much less significant[8]. 
 
After reaching the lung, microorganisms multiply and cause invasive disease. The host 
defence, including humidification and filtration of air in the upper airways, epiglottic and 
cough reflexes, ciliary transport phagocytes and opsonins in the distal lung and systemic 
immunity prevent bacterial invasion[9].  In the ICU host defences are compromised as a 
result of underlying disease and the treatments given. Patients are unable to cough 
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effectively due to sedation, pain or underlying disease. Also, when intubated the 
endotracheal tube holds the vocal cords open which facilitates aspiration.  
 
2.3 Risk Factors 
Endotracheal intubation is the single most important risk factor for VAP; associated with 
3-21 fold increase in risk[10-13].  The risk is increased by the following methods: 
 
1. Sinusitis and trauma to the nasopharynx (nasotracheal tube). 
2. Impaired swallowing of secretions. 
3. Acting as a reservoir for bacterial proliferation. 
4. Increasing bacterial colonisation of the airways. 
5. Presence of a foreign body traumatising the oropharyngeal epithelium. 
6. Ischaemia secondary to cuff pressure. 
7. Impaired ciliary clearance and cough. 
8. Leakage of secretions around the cuff. 
9. The use of suction to remove secretions. 
Adapted from[14]. 
 
Microorganisms can adhere to the surface of the endotracheal tube and form a biofilm.  
This provides a reservoir of microorganisms, and they are highly resistant to both host 
defence and antimicrobial drugs[15]. 
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Duration of mechanical ventilation is an important risk factor for the development of 
VAP.  Cook et al.[6] reported a cumulative increased risk of VAP with time, with 3% per 
day in the first week, 2% per day in the second week and 1% per day in the third week.  
Other studies have confirmed that the risk of VAP increased as the duration of 
mechanical ventilation increased and that the risk is highest in the first 8-10 days[11, 16, 
17].  Reintubation, urgent intubation and massive aspiration are also associated with a 
high incidence of VAP[18].  The table below summarises the independent risk factors for 
VAP. 
Host factors Intervention factors Other factors 
Age > 60 yr Duration of MV Season: Autumn, Winter 
Severity of illness Reintubation  
Organ Failure PEEP  
Poor Nutritional state Frequent ventilator circuit changes  
Upper abdominal/thoracic surgery Nasogastric tube  
ARDS Intracranial pressure monitoring  
Chronic lung disease Paralysis, sedation  
Neuromuscular disease H2 blockers and/or antacids  
Trauma, burns >4 unit blood transfusion  
Coma, decreased conscious level Supine head position  
Large volume aspiration Transport out of ICU  
Upper respiratory tract colonisation   
Gastric colonisation and pH   
Sinusitis   
Table 2.1 Risk factors for VAP.  Adapted from [18]. 
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Nasogastric tubes are commonly used in the ICU for both feeding and drainage of 
stomach contents; especially in surgical patients.  These tubes impair the function of the 
gastro-oesophageal sphincter and increase the risk of sinusitis, oropharyngeal 
colonization and reflux, all of which may lead to migration of bacteria and pneumonia[9, 
19].  Enteral feeding via the nasogastric route may predispose to VAP by elevating 
gastric pH, leading to gastric colonisation and increasing the risk of reflux and aspiration 
by causing gastric distension[6, 20, 21]. 
 
2.4 Aetiology of VAP 
The causative organisms vary depending on patient demographics, methods of diagnosis, 
duration of hospital and ICU stay and the local antibiotic policy.  Gram-negative bacteria 
are the most common causative agent reported in several studies[18].  In National 
Nosocomial Infection Surveillance (NNIS) data, although Staphylococcus aureus was the 
most commonly reported isolate (17%), 59% of all reported isolates were Gram-
negative[22].  It is worth discussing some of the important individual pathogens that 
cause VAP. 
 
Streptococcus pneumonia is a Gram-positive diplococcus that colonises the upper 
respiratory tract and invades the lung after microaspiration of oropharyngeal secretions.  
It is the most common cause of community acquired pneumonia[23].  Although antibiotic 
resistance is a growing problem,[24, 25] most S. pneumonia isolates remain susceptible 
to traditional β-lactam antibiotics[26, 27].  It causes VAP predominantly in the early days 
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after intubation and is rapidly cleared after beginning antibiotic therapy[28].  The main 
risk factors for VAP caused by this pathogen are smoking, chronic obstructive pulmonary 
disease (COPD) and the absence of prior antibiotic therapy. 
 
Haemophilus influenza is a small Gram-negative coccobacillus. In common with S. 
pneumoniae it is fastidious and easily eradicated by antibiotic therapy[28] and causes 
VAP most often early after the initiation of mechanical ventilation. Risk factors as a 
cause of VAP include COPD and the absence of prior antibiotic therapy[29]. 
 
Staphylococcus aureus is a Gram-positive coccus that is one of the most important causes 
of nosocomial infections generally and of VAP[30]. Staphylococci cause VAP 
throughout the course of critical illness.  The prevalence of methicillin-resistant S. aureus  
(MRSA) strains is increasing, even in community isolates[31].  Proven risk factors for 
VAP caused by methicillin-sensitive S. aureus include younger age, traumatic coma and 
neurosurgical problems[32].  Risk factors for VAP caused by MRSA include COPD, 
longer duration of mechanical ventilation, prior antibiotic therapy, prior steroid treatment 
and prior bronchoscopy. The likelihood that VAP is due to MRSA becomes nearly 
certain if the patient has received antibiotic treatment and the onset of VAP is later in the 
hospital course[33] 
  
Enterobacteriaceae or enteric Gram-negative bacilli normally reside in the lower 
gastrointestinal tract.  Antibiotic therapy and critical illness can suppress the normal 
bacterial flora and lead to overgrowth of these species in the gut and colonisation of the 
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skin and the respiratory and upper GI tracts.  Some of these organisms have acquired 
resistance to penicillin and cephalosporin antibiotics[32].  This has implications for 
antibiotic therapy. 
 
Pseudomonas aeruginosa is an aerobic nonfermenting Gram-negative bacillus and is 
intrinsically resistant to many classes of antibiotics.  It is the most common antibiotic 
resistant pathogen causing VAP[2].  Unlike many other causes of VAP, Pseudomonas is 
consistently associated with a measurable attributable mortality[32].  Pseudomonas VAP 
is unusual early in the hospital course in previously healthy patients.  It typically occurs 
only if risk factors are present, including COPD, prolonged duration of mechanical 
ventilation and prior antibiotic therapy.  It is difficult to eradicate from the airways and 
persistent or recurrent episodes of pneumonia are common[28]. 
 
Acinetobacter species are aerobic nonfermenting Gram-negative bacilli that are widely 
distributed in soil and fresh water sources.  Acinetobacter species have traditionally been 
considered to be low virulence, and clinical isolates have often been considered to 
represent colonisation rather than infection[34]. Recently, there has been increasing 
recognition of these species as important causes of nosocomial infection, particularly in 
critically ill patients[32]. They are readily spread between patients and have the ability to 
survive on health care workers hands and inanimate environmental surfaces[32].  They 
also have intrinsic resistance to many common antibiotics[32]. 
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The figure below shows the relative frequencies of routine microbiological pathogens in 
VAP. 
 
 
 
Fig. 2.1 The relative proportions of common causes of VAP are shown from 1,689 
bronchoscopically confirmed cases involving 2,490 individual isolates reported in 24 
published studies.  Data from Chastre 2002[2]. 
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2.5 Polymicrobial Infections 
Polymicrobial infection occurs in many cases of VAP.  Combes and colleagues have 
reported a series of VAP cases using the first episode of VAP as the unit of analysis.  
Forty eight percent of their 124 cases were polymicrobial, with up to 4 separate important 
isolates from individual patients.  In these cases, the clinical features and outcomes and 
the prevalence of specific individual pathogens in the polymicrobial cases did not appear 
to differ from cases with only one infecting organism[35]. 
 
2.6 Multidrug-Resistant VAP Pathogens 
Many of the organisms that cause VAP, especially Pseudomonas, Acinetobacter, and 
Stenotrophomonas species, and MRSA typically display high levels of antibiotic 
resistance.  These organisms, and enteric Gram-negative bacilli expressing extended-
spectrum β-lactamases, have been termed “potentially drug-resistant” pathogens[36] or 
“multidrug resistant” pathogens[37].  In order to account for this the empiric antibiotic 
regime must include multiple agents with an extremely broad spectrum of activity[36].  
However, unnecessarily broad antibiotic coverage can have adverse consequences.  These 
include encouraging the development of more resistant bacterial strains, higher rates of 
antibiotic-related complications and increased costs[38].  A major goal of VAP 
management is to minimise the unnecessary use of antibiotics, but it is essential to be 
able to predict when antibiotic coverage for multiple drug-resistant pathogens is 
necessary, in order to avoid under treatment of these infections[32]. 
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The duration of mechanical ventilation preceding the onset of pneumonia is the single 
most important determinant of the causative agent(s) of VAP and the likelihood of 
multidrug resistant organisms being responsible.  VAP has traditionally been classified as 
either “early-onset” (within 4-7 days of intubation), or “late-onset” (if it occurs after 4-7 
days).  Early-onset VAP is commonly caused by Haemophilus species, streptococci 
including S. pneumoniae, MRSA, and sensitive strains of Enterobacteriaceae.  These 
organisms can also be responsible for late-onset VAP, but multidrug resistant organisms 
are more commonly encountered in this period[37].  In some studies the early/late onset 
distinction is quite apparent.  In one study all 11 potentially multidrug resistant pathogens 
(out of a total of 40) occurred after 5 days of mechanical ventilation[39].  The presence of 
multidrug resistant organisms in the early period should prompt a search for other risk 
factors for this type of infection[40]. 
 
Extended periods in hospital prior to the requirement for mechanical ventilation could 
also be a risk factor for the development of multi drug resistant VAP in the early period 
[37, 41, 42].  Medical co-morbidities including HIV infection, malignancy and COPD as 
well as pre-hospital intubation predicted infection with multidrug resistant organisms in a 
study of trauma patients[43].  The use of antibiotics prior to intubation appears to be a 
“double edged sword”.  It may decrease the risk of early VAP due to antibiotic sensitive 
Gram-positive cocci and H. Influenza, but it increases the risk of VAP due to 
Pseudomonas, MRSA, and other multi drug resistant pathogens in the later stages of the 
hospital stay[36, 44, 45]. Trouillet et al. identified three variables independently 
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associated with infection by a multi drug resistant pathogen: duration of mechanical 
ventilation more than 7 days (odds ratio 6.0), prior antibiotic use (odds ratio 13.5) and 
prior broad spectrum antibiotic use (odds ratio 4.1)[36]. 
 
2.7 Antibiotics and VAP 
The use of antibiotics for the treatment of VAP is an area of much debate within the 
Intensive Care community.  The main areas of debate are: 
 
1. When to initiate antibiotic therapy 
2. The use of empirical antibiotic therapy 
3. Descalation and duration of antibiotic therapy 
4. Antibiotic resistance 
 
2.7.1 When to initiate antibiotic therapy 
This decision is crucial in the management of VAP as it has been shown that delays in the 
initiation of appropriate therapy are associated with increased morbidity and mortality 
[46-48].  The difficulty in making the diagnosis in the first place and the unreliability of 
clinical diagnosis make this an area of ongoing debate.  Many units have developed their 
own local protocols based on a variety of diagnostic techniques including CPIS, 
radiological investigations and microbiology techniques.  
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The diagram overleaf demonstrates a diagnostic and therapeutic management strategy 
based on the use of invasive sampling techniques such as BAL.  The use of such a 
strategy means that therapeutic decisions are tightly protocol driven based on the results 
of direct examination of distal pulmonary samples and results of quantitative cultures.  It 
is argued that the use of such a strategy improves diagnostic accuracy and facilitates 
decisions on whether or not to treat.  This in turn improves outcome and reduces 
unnecessary use of antibiotics. 
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Fig 2.2. Diagnostic and therapeutic strategy applied to patients with a clinical suspicion 
of VAP according to the “invasive” strategy. From Chastre 2005[49]. 
 
However Muscedere et al.[50] reviewed studies that examined the impact of invasive 
versus noninvasive techniques (such as endotracheal aspirates) on patient important 
outcomes.  They did not find that the use of invasive sampling techniques with 
quantitative cultures in the populations studied improved clinical outcome.  In addition, 
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as these techniques are more intrusive, expensive, and less universally available, they did 
not recommend their routine use. 
 
The following points must be considered when evaluating this recommendation.  Firstly, 
it is not possible to distinguish between the various invasive techniques in use to obtain 
distal pulmonary tree samples for quantitative cultures as these have not been studied 
individually with regard to their ability to affect clinical outcome. Second, this 
recommendation does not apply to immunocompromised patients.  Third, this 
recommendation is based on the assumption that a decision has already been made to 
treat with appropriate antibiotics until culture results are available.  This is general but 
not universal practice throughout the world. Finally, one study demonstrated potential 
benefit to reducing antibiotic use by including the findings from immediate Gram stain of 
bronchoscopic samples into the decision on whether or not to initiate antibiotics[51].  
However the validity and clinical reproducibility of these data are challenged by 
subsequent publications demonstrating a high error rate if decisions to withhold 
antibiotics are made on the basis of Gram stain findings[50]. 
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For VAP treatment, the recommendation that antibiotics be initiated at the time that VAP 
is suspected is supported by one randomised clinical trial[47].  Although this trial showed 
only a trend towards improved outcomes with empiric therapy at the time of VAP 
suspicion, there is a large amount of supporting evidence in the form of observational 
data that associates delays in instituting adequate therapy with worse outcomes[46, 52-
55].  Similarly, a randomised controlled trial in which a large proportion of the patients 
had VAP, showed the institution of empiric antibiotic therapy at the time of suspicion of 
infection resulted in improved outcomes as compared to culture-directed therapy[56].  
 
2.7.2 Empirical antibiotic therapy 
Empirical antibiotic therapy is defined for our purposes as the initiation of antibiotic 
therapy at the time of VAP suspicion and delayed culture-directed therapy is defined as 
the initiation of antibiotic therapy for VAP when culture reports are available.  We have 
already discussed that there is little evidence to support the use of delayed antibiotic 
therapy, indeed there is considerable evidence to show it results in patient harm. 
 
One of the difficulties with the use of empiric antibiotic therapy is the selection of 
antibiotic drug or drugs.  The initiation of empiric therapy is essentially the use of “best 
guess” antibiotic based on local policies and resistance patterns.  This usually involves 
the use of broad spectrum drugs which have activity against a wide range of pathogens.  
The downside of this is that it can encourage the emergence of drug resistant organisms.  
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Broad spectrum antibiotic use also increases the rate of Clostridium Difficile infection in 
patients receiving these antibiotics. 
 
Muscedere et al[50] reviewed 5 trials that compared empiric broad spectrum 
monotherapy to combination therapy in patients with VAP.  They concluded that there is 
no advantage to combination therapy.  These trials did not demonstrate any differences in 
mortality or clinical response rates.  However, the benefit of a reduction in antibiotic use 
and cost favours monotherapy.  Empiric therapy should be based on local resistance 
patterns and patient risk factors.  In situations where high rates of resistance are present, 2 
or more antibiotic agents may be justified to ensure that each potential pathogen is 
covered by at least one agent.  
 
Once treatment has been started the prompt cessation of antibiotic therapy if pneumonia 
is not confirmed has several advantages.  Reduced costs, side effects and drug 
interactions are all important advantages as well as the reduced likelihood of the 
emergence of resistant organisms. Other sites of infection requiring definitive therapy 
may be more likely to be discovered because their signs are not being masked by 
antibiotics. 
 
Several studies have shown that it may be safe to withdraw the empiric therapy when 
quantitative cultures are sterile or show a bacterial concentration that is lower than the 
threshold used to define infection[51, 57, 58].  These thresholds must not be used in 
patients who had recent changes or new antibiotics prior to sampling.  It should be 
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recognised that these studies were not designed to specifically address the issue of 
withdrawing therapy, and the decision to stop antibiotics was made by the clinician on 
both clinical status of the patient and culture results. 
 
The level of clinical suspicion defines the context in which microbiology data should be 
interpreted.  Only a test with a high likelihood ratio (for example a positive blood culture) 
should make the clinician continue antibiotics in the setting of low clinical suspicion.  On 
the other hand, a test with a lower likelihood ratio such as a positive tracheal aspirate 
culture might be dismissed as a contaminant. 
 
2.7.3 Descalation and the duration of antibiotic therapy 
Descalation is the switch from broad spectrum empirical antibiotic therapy to narrow 
spectrum antibiotics based on positive culture results.  
 
The traditional approach to infection has been to narrow the antibiotic spectrum to the 
most specific, safest and least costly drug based on definitive culture result.  This 
approach is more difficult in the context of VAP because of concerns about sensitivity 
and specificity of virtually all culture techniques. 
 
The most clear cut situation in which bacteria are cultured from blood, open lung biopsy 
or pleural fluid is rare.  In these scenarios treatment can be based on culture results with 
confidence.  With somewhat less confidence, treatment can be adjusted or focused on the 
basis of invasive (PSB or BAL) cultures.  In cases where these were performed prior to 
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any antibiotic changes, narrowing the antibiotic spectrum based on the quantitative 
cultures (descalation) is logical.  In patients who had antibiotic changes before 
bronchoscopy, patients who are clinically deteriorating despite “subthreshold” or 
negative cultures, or patients who are found to be on effective empiric therapy but are 
worsening nonetheless, the results of invasive cultures should be interpreted with caution.   
 
The duration of antibiotic therapy for VAP is another controversial area.  Deciding on the 
length of treatment requires the balancing of the risk of either failure or relapse with short 
treatment courses against the concerns surrounding antibiotic overuse with more 
prolonged courses of antibiotics[59].  The belief that longer antibiotic courses pose no 
risk to the patient as long as the drugs used are effective against the infecting organisms 
is false.  Despite initial resolution of clinical parameters of infection within 6 days of 
instituting appropriate antibiotic therapy, Denneson et al.[28] noted that Gram negative 
pathogens re-grew to colonise the trachea during the second week of therapy.  This led to 
recurrence of VAP but now with strains that were resistant to the original antibiotics 
used[28]. 
 
Shorter, 7 day courses of antibiotics have been proposed for VAP[28].  Chastre et al. [59] 
compared discontinuing antibiotics at 8 days with 15 days.  There were no significant 
differences in mortality, length of stay, or duration of mechanical ventilation.  The shorter 
course was associated with a reduction in antibiotic use and a reduction in the emergence 
of resistance.  A higher percentage of patients treated with 8 days of antibiotics 
developed recurrence of lung infection secondary to nonfermenting Gram negative 
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bacteria, but this was not associated with worsened clinical outcomes.  Among those who 
developed a recurrent VAP, multiresistant organisms emerged significantly less often in 
the group who received 8 days of therapy. 
 
Therefore in patients who receive adequate initial antibiotic therapy, a total of 8 days of 
antibiotic therapy can be recommended[50].  
 
2.7.3 Antibiotic Resistance 
Many of the issues surrounding this point have been discussed in the preceding text; 
including the use of empirical antibiotic therapy and descalation.  Trouillet et al.[36] 
prospectively and specifically evaluated risk factors for infection with potentially drug 
resistant pathogens in 135 cases of bronchoscopically proven VAP.  Multivarate analysis 
identified 3 variables independently associated with infection by a potentially drug 
resistant pathogen: 
 
1. Duration of mechanical ventilation> 7 days. (odds ratio 6.0) 
2. Prior antibiotic use. (odds ratio 13.5) 
3. Prior broad spectrum antibiotic use. (odds ratio 4.1) 
 
These findings have serious implications for empiric antibiotic choice.  The antimicrobial 
susceptibility profiles of the isolates recovered in this study became increasingly resistant 
with increased duration of mechanical ventilation and with prior exposure to antibiotics. 
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2.8 Current methods of Diagnosing VAP 
VAP is usually suspected when a patient develops a new or progressive pulmonary 
infiltrate with fever, raised white blood cell count and purulent tracheobronchial 
secretions[60].  However these signs are not specific to VAP and the diagnosis can be 
difficult to make. 
 
2.8.1 Clinical Pulmonary Infection Score (CPIS) 
CPIS was originally proposed as a way of combining clinical parameters with 
microbiological testing as a way of diagnosing VAP [61].  A modified version of the 
original CPIS, used in this work is shown below. The accuracy of CPIS has been 
questioned[62]. 
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VAP clinical diagnosis criteria 
Temp °C  
 
>or equal to 36.5 and <or equal to 38.4  = 0 points 
>or equal to 38.5 and <or equal to 38.9  = 1 point 
>or equal to 39 and <or equal to 36.0     = 2 points 
 
White cell count/mm
3 
  
>or equal to 4000 and <or equal to 11000
     
= 0 points 
<4000
 
or > 11000     = 1 point 
 
Tracheal secretions 
  
No secretions       = 0 points 
Non purulent secretions    = 1 point 
Purulent secretions     = 2 points  
 
Oxygenation: PaO2/FiO2, kPa  
>31.6 or ARDS     = 0 points 
< or equal to 31.6 and no ARDS   = 2 points 
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CXR findings 
 
No infiltrates      = 0 points 
Diffuse/patchy infiltrates   = 1 point 
Localised infiltrates    = 2 points 
 
Progression of infiltrates 
 
No radiographic progression   = 0 points 
Radiographic progression   = 2 points 
(after exclusion of CHF and ARDS) 
 
Culture of tracheal aspirates 
 
Pathogenic bacteria cultured in rare or light growth/no growth = 0 points 
Pathogenic bacteria cultured in moderate/heavy growth  = 1 point 
Pathogenic bacteria on Gram stain     = ADD 1 point 
TOTAL SCORE:    /12 (Score 6 or more significant) 
  
Adapted from Pugin et al.  1991 
CHF is congestive heart failure; ARDS is acute respiratory distress syndrome. 
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2.8.2 Radiological Investigations 
Chest x-ray is a routine and accepted investigation frequently used in the diagnosis of 
VAP.  However chest x-ray changes can take days to become apparent after infection.  
Computed Tomography (CT) scanning of the chest has a higher sensitivity in diagnosing 
VAP than chest x-ray.  In one study CT scan detected 26% of opacities that were not 
detected on portable chest x-ray[63].   However it has the distinct disadvantage that 
patients need to be transported from the relative safety of the ICU to the CT scanner.  
This is not always possible when the patient is unstable.  Both of these investigations 
have a false positive rate and can be normal in the presence of VAP.  The overall 
radiographic sensitivity of a pulmonary opacity consistent with pneumonia on chest x-ray 
is only 27%-35%[63]. 
 
 
 
 
 
 
 
 
 
Fig. 2.3 Radiographic changes 
in VAP.  Area of consolidation 
is indicated by the arrow. 
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2.8.3 Microbiological Investigations 
Upper airway secretions can be cultured simply by collecting sputum samples from the 
ventilated patient.  This method of testing has the advantage of being easily reproducible 
and requires little technical expertise.    The fact that the upper airways can rapidly 
become colonised by potentially pathogenic micro-organisms after endotracheal 
intubation, even when pneumonia is not present detracts from the value of these studies.  
Thus if an organism is cultured or noted on Gram stain, it is impossible to know if it is 
the cause of a pneumonia or simply colonisation. 
 
In a study of 48 patients with respiratory failure, agreement between tracheal non 
quantitative cultures and cultures of lung tissue from open lung biopsy was only 40%.  In 
the same study, of those patients with pneumonia on lung histology, endotracheal aspirate 
had a sensitivity of 82% but a specificity of only 27%[63]. 
  
In order to improve the specificity of the diagnosis of VAP numerous studies have 
evaluated the role of quantitative cultures of respiratory secretions.  These have included 
both “blind” and bronchoscopic methods of sampling.  Bronchoalveolar Lavage (BAL) 
and protected specimen brush (PSB) are methods of sampling fluid from the distal 
airways, which can be performed “blind” or bronchoscopically guided.  Studies have 
shown no significant difference in the diagnostic accuracy of either of these methods[49].  
Protected specimen brush testing is an alternative to BAL sampling.  The preferred 
method of sampling is uncertain [64, 65]. 
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VAP spreads to the blood or pleural space in <10% of cases.  Despite this, if an organism 
known to cause pneumonia is cultured on a clinical background of suspected pneumonia, 
treatment is warranted.  It is important to note that the sensitivity of blood cultures for the 
diagnosis of VAP is 26%[66], but also, that when positive, the organisms may originate 
from an extrapulmonary site of infection in as many as 64% of cases; even in the 
presence of VAP[63]. 
 
2.9 New Diagnostic Markers of VAP 
2.9.1 Procalcitonin  
(http://www.procalcitonin.com/default.aspx?tree=_2_3&key=aboutpct22) 
Procalcitonin (PCT) is a 116 amino acid peptide which has been shown to play a role as 
an inflammatory mediator in systemic infection.  Its sequence is identical to the 
prohormone of calcitonin.  Under normal metabolic conditions, calcitonin is produced 
and secreted by the C-cells of the thyroid gland.  Normally the circulating levels of 
calcitonin are very low (< 0.05ng/ml). 
 
Following bacterial infections, PCT is released from all parenchymal tissues and 
differentiated cell types throughout the body.  Concentrations of PCT up to 1000ng/ml 
can be detected in cases of severe bacterial infection or sepsis.  Parenchymal cells 
(including liver, lung, kidney, adipocytes and muscle) provide the largest tissue mass and 
principal source of circulating PCT in sepsis.  The inflammatory release of PCT can be 
induced either directly via microbial toxins (eg. endotoxin) or indirectly via a humoral or 
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cell-mediated host response (eg. IL-1ß, TNF-alpha, IL-6). The induction can be 
attenuated by cytokines also released during a viral infection (eg. interferon-gamma). 
 
PCT increases after 2-3 hours following induction e.g. by endotoxin and may increase to 
levels up to several hundred nanogram per ml in severe sepsis and septic shock. After 
successful treatment intervention the procalcitonin value decreases, indicating a positive 
prognosis. Persistingly high or even further increasing levels are indicators for poor 
prognosis.  After induction, PCT increase is observed within 2-3 hours. Levels then rise 
rapidly, reaching a plateau after 6-12 hours. PCT concentrations remain high for up to 48 
hours, falling to their baseline values within the following 2 days. The half-life is about 
20 to 24 hours. 
 
PCT has also been shown to be elevated in conditions other than sepsis such as 
surgery[67] and transplant rejection[68] amongst others.  Low levels of PCT can also be 
seen in the early stages of bacterial disease or when infection is localised[69-71].  The 
use of PCT as a marker of infection therefore relies on follow up and re-evaluation of 
levels, rather than a one off measurement. 
 
In lung infection and injury circulating levels of PCT rise rapidly.  This is most likely in 
response to cytokine release from pulmonary neuro-endocrine cells and/or mononuclear 
cells[72, 73].  Duflo et al [74] stated that serum PCT had a role as a diagnostic marker of 
VAP and also that serum levels were greater in patients that died compared with those 
that survived.  With a cutoff of 3.9ng/ml sensitivity was 61% and specificity 100%.  
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These results have been questioned by other studies which have shown a poor sensitivity 
of PCT for diagnosing CAP or VAP[75, 76].  This controversy suggests that PCT should 
be used as a complementary tool for the diagnosis of VAP alongside established 
diagnostic methods. 
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2.9.2 The soluble triggering receptor expressed on myeloid cells-1 (sTREM-1) 
This has been identified as a molecule involved in the inflammatory response which 
belongs to the immunoglobulin superfamily.  It is expressed on the surface of neutrophils, 
mature monocytes and macrophages[77].  TREM-1 is not upregulated in samples from 
patients with noninfective or inflammatory conditions such as psoriasis, ulcerative colitis 
or vasculitis caused by immune complexes[77].  Besides TREM-1 (which is the 
membranous form) a soluble form (sTREM-1) exists that is specifically released in 
several inflammatory processes[76].  The detection of this soluble form in body fluids 
shows promise as a diagnostic test, especially during severe sepsis and pneumonia, and in 
patients who have received previous antimicrobial drugs, since its determination is quick, 
cheap and can be performed in batches or for individual samples.  No sTREM-1 assay is 
commercially available at present. 
 
The diagnostic importance of sTREM-1 in pneumonia has been investigated in 
mechanically ventilated patients with a clinical suspicion of pneumonia[78].  The 
detection of sTREM-1 in BAL fluid was more accurate than clinical findings or 
laboratory testing (including CPIS and Procalcitonin) in identifying the presence of 
bacterial pneumonia.  However, sTREM-1 was detected in the BAL fluid in 6/64 patients 
who did not have pneumonia. 
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Determann et al.[79] measured sTREM-1 levels in the BAL fluid on alternate days in 28 
critically ill, mechanically ventilated patients from the day ventilation was initiated until 
weaning.  Nine patients developed VAP whilst nineteen did not.  In those who developed 
VAP, an increase in sTREM-1 levels were seen in BAL fluid until the day of diagnosis.  
In contrast sTREM-1 was barely detectable in the BAL fluid of those who did not 
develop VAP.  Using a cutoff value of 200pg/ml on the day of VAP diagnosis has a 
diagnostic sensitivity of 75% and a specificity of 84%.  On this basis sTREM-1 appears 
to be a reliable marker for VAP but its sensitivity is not 100%. 
 
2.9.3 Determination of bacterial endotoxin in BAL fluid 
More than 80% of VAP is caused by Gram-negative bacteria, which are associated with a 
high mortality.  It has been postulated that the measurement of endotoxin in BAL fluid 
may permit the rapid diagnosis of Gram-negative bacterial pneumonia.  Pugin et al.[80] 
reported that patients with VAP due to Gram-negative bacteria could be identified 
accurately by having an endotoxin concentration of more than 6 endotoxin units/ml in 
their BAL fluid.  Kollef et al.[81] performed a study in which 63 patients underwent 71 
episodes of BAL sampling and quantitative cultures.  A cutoff value of more than 5 
endotoxin units/ml yielded a 100% sensitivity and 75% specificity for the diagnosis of 
Gram-negative pneumonia.  The findings of these and other studies indicate that this 
method may be a useful adjunct for the rapid diagnosis of Gram-negative pneumonia. 
Several biomarkers are showing promise as early and accurate tests for the presence of 
lung infection in the mechanically ventilated patient.  These assays may be used as 
screening tools to identify those who may benefit from microbiological testing and 
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empirical antibiotic therapy.  Raised PCT and sTREM-1 also indicate a host 
inflammatory response to infection, and could be markers of those at risk of organ 
dysfunction and failure.  Neither of these markers however can be used as a surrogate for 
bacterial infection.  As with all diagnostic tests, the results must be interpreted with care 
in the context of the clinical state of the patient.  
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Chapter 3 
Breath Analysis for the Detection of Disease
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3.1 Introduction 
In this chapter we will focus on the science that underlies the principles of operation of 
electronic noses (Enoses), Gas Chromatography-Mass Spectrometry (GC-MS) and 
Selected Ion Flow Transfer-Mass Spectrometry (SIFT-MS). These are the technologies 
that are currently at the forefront of breath analysis.  Breath analysis is a technique that is 
gaining popularity as the search for novel diagnostic methods gathers pace.  Breath 
analysis is attractive because it offers the potential for rapid, non invasive near patient 
diagnosis.  The list of disease applications below is by no means exhaustive.  It is merely 
meant to demonstrate the wide range of applications for this technology in both 
laboratory and clinical medicine. 
 
3.1.1 Lung cancer 
In 1999 Phillips et al.[82] found a combination of 22 VOCs in the breath of lung cancer 
patients which could be used to identify those with the disease.  The compounds were 
identified using GC-MS and were predominantly alkanes, alkane derivatives and benzene 
derivatives.  This was a cross-sectional study which looked at breath samples from 108 
patients with abnormal chest x-rays.  Patients then underwent bronchoscopy and 
histological or cytological sampling.  60 patients were confirmed to have lung cancer.  
Patients underwent breath sampling within 24 hours prior to bronchoscopy.  The breath 
samples were analysed using GC-MS techniques. 
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Forward stepwise discriminant analysis was used to identify VOCs that could 
discriminate between patients with and without lung cancer.  67 VOCs were common to 
the breath samples of 62 patients, of these VOCs 22 were selected by discriminate 
analysis.  Using this approach for the detection of stage 1 lung cancer the technique had 
100% sensitivity and 81.3% specificity.  Cross validation of the technique correctly 
predicted the diagnosis in 71.7% with lung cancer and 66.7% of those without. 
 
The small number of patients with stage 1 lung cancer may have skewed the results in 
this paper as there seemed to be no increase in the predictive values of the technique as 
the lung cancer stage became more advanced.  This goes against what would be expected.  
Also as this is a cross sectional study, the predictive values of this technique when 
applied to screening an unselected population is unknown. 
 
In 2003 Di Natale et al.[83] used an electronic nose to identify lung cancer patients.  A 
total of 62 breath samples were taken from 60 individuals by the bag collection method.  
35 patients had lung cancer, 18 were used as reference subjects and 7 patients were post 
surgery for lung cancer.  100% of the lung cancer patients were correctly classified, 94% 
of the controls were correctly classified and 44% of the post surgical patients were also 
correctly classified.  The misclassified post surgical patients were classified as healthy 
controls. 
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This study is promising but contains small sample numbers.  It should also be mentioned 
that the cancer patients all had similar stage cancer, but no information about what stage 
of the disease the patients had is mentioned. 
 
In 2005 Machado et al.[84] also used an electronic nose to analyse breath samples from 
lung cancer patients.  This study used a group of 14 cancer patients and 45 non cancer 
patients (although some had lung pathology) to establish a discovery and training group.  
All 14 lung cancer patients then went into the validation group.  The validation group 
consisted of the same 14 cancer patients and 68 non cancer patients.  The non cancer 
patients were a mixture of healthy volunteers and patients with non cancer lung 
pathology.  A total of 330 of 388 breath samples collected from this group were correctly 
classified; an overall accuracy of 85%.  The electronic nose had 71.4% sensitivity and 
91.9% specificity. 
 
The cancer patients used to create the training model consisted of 13 patients with non 
small cell lung cancer and 1 patient with small cell lung cancer.  In the validation model 
patients with small cell lung cancer were misclassified; this suggests the volatile 
fingerprints of small cell and non small cell lung cancer may be different.  Also the 
VOC‟s chosen were identified using GC-MS, there is no evidence that the Enose detected 
the VOCs described in the paper. 
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3.1.2 Breast Cancer 
In 2003 Phillips et al.[85] used 22 C4-C20 alkanes found in breath to identify women 
suffering with breast cancer from those without breast cancer.  Two hundred breath 
samples were obtained from women with abnormal mammograms who subsequently 
underwent breast biopsy.  Fifty one cases of breast cancer were detected in 198 
consecutive biopsies. 
 
The breath test distinguished between women with breast cancer and healthy volunteers 
with a sensitivity of 94.1% (48/51) and a specificity of 73.8% (31/42) (cross-validated 
sensitivity 88.2% (45/51), specificity 73.8% (31/42)). Compared to women with 
abnormal mammograms and no cancer on biopsy, the breath test identified breast cancer 
with a sensitivity of 62.7% (32/51) and a specificity of 84.0% (42/50) (cross-validated 
sensitivity of 60.8% (31/51), specificity of 82.0% (41/50)). The negative predictive value 
(NPV) of a screening breath test for breast cancer was superior to a screening 
mammogram (99.93% versus 99.89%); the positive predictive value (PPV) of a screening 
mammogram was superior to a screening breath test (4.63% versus 1.29%). 
 
Again, this is a promising pilot study with small numbers. 
 
 
43 
 
 
 
 
3.1.3 Tuberculosis  
In 2004 Pavlou et al.[86] used a Bloodhound Systems BH114 electronic nose to 
distinguish sputum samples infected with Mycobacterium tuberculosis from sputum 
infected with other related bacteria.  Using the Enose combined with a neural network 
they were able to classify 100% of the TB samples correctly. 
 
3.1.4 Pneumonia 
In 2004 Hockstein et al.[87] used Enose analysis of the breath of ventilated patients in an 
intensive care unit to diagnose ventilator associated pneumonia.  He compared breath 
analysis to computed tomography (CT) of the chest.  They report an accuracy of at least 
80% when comparing e nose analysis to chest CT. 
 
Adrie et al.[88] have reported increased levels of nitric oxide in the breath of patients 
with pneumonia compared to those without pneumonia. 
 
3.1.5 Urinary Tract Infection 
In 2001 Pavlou et al.[89] used a Bloodhound Systems BH114 Enose to identify samples 
of urine that were infected with bacteria.  They were further able to identify the species of 
bacteria causing the infection. 
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The above are examples of the many potential applications for the expanding field of 
breath analysis and “smelling”.  They offer the potential for rapid and non invasive 
diagnosis, not currently available to the clinician.  The next section looks at some of the 
technologies currently in use for breath analysis.  
 
 
3.2 Electronic Noses (Enose) 
Since the time of the ancient Greeks, physicians have been aware that it is possible to 
smell disease on the breath of those afflicted.  An obvious example of this is the pear 
drop like smell of acetone in the breath of a diabetic.  Liver failure can also result in the 
characteristic “fetor hepaticas” on the breath.  Bodily fluids such as urine can also have 
distinctive smells, which are specific to disease, such as the honey like smell of urine in 
phenylketonuria 
 
The search began for an alternative way to identify these volatile fingerprints using 
cheaper and less sophisticated equipment.  Research into the interactions between various 
volatile compounds and commercially available sensors commenced.  During the 1970‟s 
attempts were made to study the possibility of using redox reactions of volatile 
compounds and amplifying volatile conductivity and the contact between volatile 
molecules and sensor-based materials.  This research resulted in the creation of the first 
“electronic nose” by Persaud & Dodd in 1981[90]. 
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They attempted to simulate the various stages of the human olfactory process using 
biochemical sensors on which volatile compounds can react, amplification and treatment 
of the sensor signal responses, and using neural networks to evaluate the key useful 
components of the data, resulting in volatile odour recognition.  Unlike GC-MS, which is 
quantitative; this approach is largely qualitative or semi-quantitative, it is however, suited 
to rapid screening because results can be obtained in minutes as opposed to days.  The 
advances in this methodology over the past ten years have allowed the rapid development 
of sensor technology together with artificial intelligence approaches[91]. 
 
 
Electronic noses have appeared in several different design types.  All these designs 
however, consist of the same three basic components.  These are: a sensor array over 
which the volatile compounds are passed, the conductance of the sensor changes 
depending on the degree of binding and results in a set of sensor signals, which are linked 
to data processing software which produces an output. 
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Fig 3.1 Schematic representation of the processing pathways in an Enose and the 
mammalian olfactory system. 
 
3.2.1 Sensor Types 
“A chemosensor is a device that is capable of converting a chemical quantity into an 
electrical signal and responds to the concentration of specific particles such as atoms, 
molecules, or ions in gases or liquids by providing an electrical signal”[92].  The type of 
chemosensors used in an electronic nose need to respond to odorous molecules in the gas 
phase, which are typically VOCs with different relative molar masses.  The following 
descriptions of sensor types are adapted from Turner & Magan[93] 
 
Electronic 
sensor array 
Pre-processor 
Pattern 
Recognition 
Chemical sensor 
array (nose) 
Olfactory bulb Brain 
Enose 
Mammalian 
Nose 
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Metal Oxide Sensors 
The oxides in these sensors contain chemically bound oxygen which can interact with the 
VOCs causing oxidation which alters the conductivity of the sensor.  Altering the 
amounts of noble metals in the sensor or changing the operating temperature will alter the 
selectivity of the sensor.  This type of sensor is resistant to humidity and ageing effects 
but they are susceptible to drift over time. 
 
Conducting Polymer Sensors 
This sensor type also exhibits a change in conductance when exposed to reducible or 
oxidizable gases.  Organic conducting polymers show changes in conductivity when 
chemical substances adsorb and desorb from the polymer.  The mechanism by which the 
conductivity is changed is not clear at present. 
 
Metal oxide silicon field- effect sensors (MOSFET) 
These are related to metal oxide sensors but the output signal is obtained from a change 
in potential when the volatile molecules react at a catalytic surface.  They operate at 100-
200 degrees centigrade. 
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Gravimetric Odour sensors 
These are based on piezoelectric crystals coated with a suitable sorbent membrane.  
Detection of vapour molecules can then be achieved by their effect on the propagation of 
the acoustic wave causing changes in the resonant frequency and the wave velocity.  The 
selectivity of these sensors is dependent on the thickness of the coating. 
 
Surface acoustic-wave devices 
These are an alternative to the above sensors and are based on waves that are emitted 
along the surface of a crystal by the electric field of surface-deposited aluminium 
electrodes. 
 
Optical sensors 
These function using an optical phenomenon in which incident light excites the volatile 
analyte.  The resulting signal can be measured in the resulting absorbance, reflectance, 
fluorescence or chemiluminescence. 
 
Electrochemical sensors 
This class of sensor was amongst the first to be used in an electronic nose format.  They 
contain electrodes and an electrolyte, the responses generated being dependent on the 
electrochemical characteristics of the volatile analyte.  At the working electrode, the 
analyte is either oxidized or reduced, with the opposite reaction occurring at the counter 
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electrode.  The voltage generated by the reactions between the electrodes is measured and 
has been used to detect CO2, SO2 and H2S. 
 
The most important point to remember is that total specificity is not required.  Using 
multiple approaches it is sufficient for elements of the sensor array to react differently to 
various compounds allowing discrimination between samples. 
 
As time goes on more is being demanded of sensor technology.  The questions being 
asked are more complex and the challenge is to develop new sensor technologies to keep 
pace with the ever increasing demands.  Without high quality sensors and good 
performance, we have little chance of collecting good data to answer these questions.  
New sensor types are being developed which will give improved consistency and 
sensitivity along with greater shelf life and reduced susceptibility to humidity and 
temperature variation. 
 
3.3 Gas Chromatography 
The first attempts to use breath as a way of gaining information on the physiological state 
of the human body were using GC-MS.  As the name implies this method is actually two 
distinct technologies combined to form a powerful analytical tool.  Gas chromatography 
separates the components of a mixture of chemicals and mass spectrometry characterises 
each of the components individually.  By combining the two techniques as described it is 
possible to both qualitatively and quantitatively evaluate solutions or gases containing 
multiple chemical constituents. 
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Generally speaking, chromatography is used to separate mixtures of chemicals into their 
individual components; once these are isolated they can be individually evaluated.  
Separation occurs when the sample mixture is introduced (usually by injection) into a 
mobile phase.  In gas chromatography, the mobile phase is an inert gas such as helium.   
 
The mobile phase then carries the sample mixture through into a stationary phase.  This is 
usually a chemical that can selectively attract components in a sample mixture.  This is 
usually contained in a tube of some description which is referred to as a column.  
Columns can be made of glass or stainless steel and come in various sizes. 
 
The mixture of compounds in the mobile phase then interacts with the stationary phase.  
Each compound in the mixture interacts at a different rate; those that interact the fastest 
will exit (elute from) the column first.  By altering the characteristics of the mobile and 
stationary phases, different mixtures of chemicals can be separated.  This separation 
process can be affected further by changing the temperature of the stationary phase or the 
pressure of the mobile phase. 
 
 
The column is held in an oven that can be programmed to increase the temperature 
gradually (ramped) which helps with separation.  As the temperature increases, 
compounds with lower boiling points elute from the column sooner than those with 
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higher boiling points.  Therefore, there are two distinct separating forces, temperature and 
stationary phase interactions mentioned earlier. 
 
As the eluted compounds leave the column they enter a detector, this is capable of 
generating an electronic signal whenever the presence of a compound is detected.  The 
greater the concentration, the bigger the signal.  This signal is then interpreted by a 
computer.  The time from when the injection is made (time zero) to when elution occurs 
is referred to as the retention time. 
 
  
 
 
Fig 3.2 Chromatogram of Kerosene.  From www.las.perkinelmer.com 
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The above figure shows a chromatogram generated by a GC for kerosene.  Each of the 
peaks represents the signal generated when a compound elutes from the column into the 
detector.  The x-axis shows the retention time (RT), and the y-axis shows the intensity 
(abundance) of the signal.  Each peak represents an individual component separated from 
the kerosene. 
 
If the GC conditions (temperature ramp, column type etc.) are the same, a given 
compound will always elute from the column at nearly the same RT.  By knowing the RT 
for a given compound, we can make assumptions about the identity of that compound.  
However, compounds with similar properties will often have the same retention times.  
Therefore more information is needed before the identification of a compound in a 
sample containing a mixture of unknown compounds can be made. 
 
3.4 Mass Spectrometry 
As the individual compounds elute from the GC column, they enter the mass 
spectrometer (electron ionisation) detector.  They are bombarded with a stream of 
electrons causing them to break apart into fragments.  These are pieces of the original 
molecules of varying sizes. 
 
The fragments are charged ions with a certain mass.  The mass of the fragment divided 
by the charge is called the mass to charge ratio (M/Z).  Since most fragments have a 
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charge of +1, the M/Z usually represents the molecular weight of the fragment.  A group 
of four magnets (called a quadropole) focuses each of the fragments through a slit and 
into the detector.  The quadropoles are controlled by the computer to direct only certain 
M/Z fragments through the slit.  The rest are deflected away.  The computer cycles the 
quadropoles through different M/Z‟s individually until a range of M/Z‟s are covered.  
This occurs many times a second.  Each cycle of ranges is referred to as a scan. 
 
The computer records a graph for each scan.  The x-axis represents M/Z ratios.  The y-
axis represents the signal intensity (abundance) for each of the fragments detected during 
the scan.  This graph is referred to as a mass spectrum. 
 
 
  
 Fig.3.3 Mass spectrum of DDT. 
 From http://www.unsolvedmysteries.oregonstate.edu/MS_06 
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The mass spectrum generated by a given chemical compound is essentially the same 
every time.  Therefore, the mass spectrum is a fingerprint for the molecule.  This can then 
be used to identify the compound in question.  The computer usually compares the mass 
spectrum from an unknown compound with a library of known mass spectra in order to 
identify the compound. 
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3.5 Gas Chromatography-Mass Spectrometry (GC-MS) 
It can be seen from the above discussion that combination of these two analytical 
technologies produces a powerful tool for the identification of compounds.  Not only can 
a researcher identify the individual components he or she can also determine the 
quantities (concentrations) of each of the components. 
 
 
 
 
 
Fig. 3.4 Schematic illustration of a GC-MS machine.  
From http://www.chem.arizona.edu/massspec/intro_html/intro.html  
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3.6 Origins of endogenous volatile biomarkers 
Of the hundreds of VOCs that can be identified in human breath, most are of exogenous 
origin.  Endogenous markers, which are commonly used for diagnostic purposes, are 
hydrocarbons such as ethane, pentane and isoprene; oxygen containing compounds such 
as acetone, acetaldehyde, methanol, ethanol and 2-propanol; sulphur containing 
compounds such as dimethylsulfide, methyl and ethyl mercaptans; and carbon disulfide 
and nitrogen containing substances such as ammonia and dimethyl/trimethylamine.  In 
order to assess the physiological importance and diagnostic potential of these compounds, 
the biochemical pathways of production need to be understood[94]. 
 
3.6.1 Saturated hydrocarbons 
Lipid peroxidation is a chain reaction initiated by the removal of an allylic hydrogen 
atom through reactive oxygen species (ROS).  The radical generated in this reaction is 
conjugated, peroxidised by oxygen and then undergoes further reactions.  Saturated 
hydrocarbons such as ethane and pentane are generated in this way from omega3 and 
omega6 fatty acids respectively.  Aldehydes such as malondialdehyde are generated 
along the same pathway.  Omega3 and omega6 fatty acids are basic components of cell 
membranes.  In vitro and in vivo studies have demonstrated an association between 
clinical conditions with high peroxidative activity and the exhalation of ethane and 
pentane[95].  As a result, these hydrocarbons are considered as in vitro and in vivo 
markers of lipid peroxidation.  Although there are other potential sources of 
hydrocarbons in the body, such as protein oxidation and colonic bacterial metabolism, 
these are apparently of limited importance and do not interfere with interpretation of the 
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hydrocarbon breath test for ethane and pentane[96].  Propane and butane are mainly 
formed from protein oxidation and faecal flora, and their role as markers of lipid 
peroxidation is uncertain.  
 
Due to the physiological ratio of omega3 to omega6 fatty acids, four times more pentane 
than ethane is generated through lipid peroxidation.  Pentane, but not ethane, may be 
easily metabolised by hepatic cytochrome P450 enzymes[97].  As a result, exhaled 
pentane concentrations must be interpreted cautiously whenever liver function varies 
between patients or during the sampling period. 
 
Hydrocarbons as stable end products of lipid peroxidation show only low solubility in 
blood and are therefore excreted into breath within minutes of their formation in tissues.  
Hence, exhaled concentrations of ethane and n-pentane can be used to monitor the degree 
of oxidative damage in the body[98, 99]. 
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3.6.2 Unsaturated hydrocarbons 
Isoprene (2-methylbutadiene-1,3) is ubiquitous in human breath and thought to be formed 
along the mevalonic pathway of cholesterol synthesis.  The parallel decrease in isoprene 
secretion and sterol synthesis caused by acute or chronic lovastatin administration (a drug 
that reduces cholesterol synthesis) suggests that breath isoprene is derived from the 
cholesterol synthesis pathway in humans in vivo[100].  A small fraction of exhaled 
isoprene may be of bacterial origin[101]. 
 
There is experimental evidence that isoprene exhalation may be related to oxidative 
damage to the fluid lining of the lung[102] and the body[103].  Human breath isoprene 
concentrations show a circadian rhythm with a maximum at around 06:00 and a 
minimum at around 18:00.  Concentrations of breath isoprene also seem to be age 
dependent, being significantly lower in children[104]. 
 
3.6.3 Oxygen-Containing Compounds 
Acetone is one of the most abundant compounds in human breath.  It is produced by 
hepatocytes via decarboxylation of excess Acetyl-CoA.  Acetone is formed by 
decarboxylation of acetoacetate, which derives from lipolysis or lipid peroxidation.  
Ketone bodies such as acetone are oxidised via the Krebs cycle in peripheral tissue.  
Ketone bodies in blood are increased in ketonemic subjects in times of fasting, starving 
or during diet.  Breath acetone concentrations are increased in patients with uncontrolled 
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diabetes mellitus[105].  As acetone is produced by spontaneous decarboxylation of 
acetoacetate, it is impossible to quantify the fraction that arises from lipid peroxidation. 
 
Acetaldehyde is probably produced by oxidation of endogenous ethanol.  As a result, 
acetaldehyde concentrations in breath are always lower than corresponding ethanol 
concentrations.   
 
Ethanol concentrations in breath of human subjects are normally very much lower than 
the levels found in human breath after alcohol ingestion.  The potential source of 
endogenous ethanol is the intestinal bacterial flora[106].  2-propanol is thought to be a 
product of an enzyme mediated reduction of acetone.  As for acetaldehyde, 
concentrations of 2-propanol in humans are always lower than acetone 
concentrations[107].  The origin of breath methanol may also be the intestinal flora. 
 
3.6.4 Sulphur-containing compounds 
Compounds such as ethyl mercaptan, dimethylsulfide ordimethyldisulfide are responsible 
for the characteristic odour in the breath of cirrhotic patients[108].  Sulphur-containing 
compounds are generated in humans by incomplete metabolism of methionine in the 
transamination pathway[109].  Mercaptans are easily oxidised to their respective 
sulphides.  Under normal conditions, concentrations of sulphur-containing compounds in 
human blood and breath are very low.  Their concentrations are increased by impaired 
liver function. 
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3.6.5 Nitrogen-containing compounds 
The characteristic odour of uraemic breath is due to elevated levels of dimethylamine and 
trimethylamine.  Significant levels of ammonia will appear in the blood if the removal of 
ammonia by its conversion into urea is limited due to impaired liver function.  Ammonia 
could also be identified in the breath of normal and in higher concentrations in uraemic 
patients[110]. 
 
3.7 Technical and methodological issues related to breath analysis 
Breath analysis has not been introduced into mainstream clinical practice despite some 
promising results in the literature.  The main stumbling blocks seem to surround technical 
problems such as sampling, preconcentration and analysis, as well as basic 
methodological issues such as normalisation and expression of data.  Generally accepted 
standards of sampling, preconcentration, and analysis do not exist.  As such, 
reproducibility and reliability of sampling methods and analytical procedures are of 
paramount importance. 
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3.7.1 Sampling 
The collection of gas samples during breath analysis represents a fundamental issue.  
Dilution and contamination of samples with dead space gas and loss of analytes during 
the sampling procedure have resulted in huge variations of substance concentrations 
between different studies.  There are two basic approaches to breath collection: 
 
1. Mixed expiratory sampling means that total breath, including dead space air, is 
collected. 
2. Alveolar sampling means that pure alveolar gas is collected. 
 
The first method has been the most widely employed as it is the simplest to perform in 
spontaneously breathing subjects and requires no additional equipment.  Endogenous 
VOC concentrations are two to three times higher in alveolar air than in mixed expiratory 
air samples.  This is because there is no dilution by dead space gas.  Alveolar gas samples 
also have the lowest concentrations of contaminants[111, 112]. 
. 
The figure below shows a schematic of a capnography trace illustrating the different 
phases of breathing.  Phase I is anatomical dead space gas which does not contain any 
endogenous VOCs or CO2.  Phase II contains a mixture of alveolar and dead space gas.  
Phase III reflects alveolar emptying and as a result, minimally changing CO2 
concentration. 
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Fig 3.5 Schematic illustration of a capnography trace showing the different phases of 
sampling.  From Miekisch et al 2004[94]. 
 
To allow distinction between exogenous and endogenous compounds some form of 
correction for background inspired air is necessary.  Different approaches to this problem 
have been utilised.  Substance concentration in ambient or inspired air have been 
measured, and an “alveolar gradient” calculated by subtracting inspiratory from 
expiratory concentrations[113].  Others have attempted to eliminate ambient 
contaminants by having patients breathe pure air for a time before sampling[98].  This 
approach is not only time consuming and cumbersome but cannot easily eliminate 
exogenous compounds merely by breathing pure air; as a result it is unlikely to be 
applicable in the clinical setting. 
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Subtraction methods such as the calculation of alveolar gradients are easier to perform, 
but they are too simplistic.  They fail to take into account the complex nature of 
pulmonary adsorption and exhalation of volatile substances.  This is a particular problem 
when the inspiratory concentrations are of the same order of magnitude as the expired 
concentrations of interest.  Expired samples may be diluted or contaminated by 
inspiratory and/or dead space ventilation, which is dependent on the breathing pattern 
[114].  Also the ventilation/perfusion ratio in the lung and alveolar concentration gradient 
of the substances affect the excretion and intake of volatile substances[115].  
 
 As the metabolic pathways of many VOCs are not understood exogenous substances 
may appear in the breath having been ingested hours or days prior to the sampling, from 
locations remote to the sampling site.  Therefore subtracting compounds from the 
inspired ambient air will not take into account these compounds which may then be 
falsely considered as endogenous.  Some compounds of interest that have been identified 
in vivo may also be metabolised prior to excretion and therefore not detected.  If the 
biochemical pathways involved in this metabolism are not understood then these 
metabolites may not be identified as compounds of interest.   
 
Sampling may be single breath or time limited.  If single-breath sampling is employed 
steps have to be taken to ensure that this single breath is representative for all subsequent 
breaths.  This is particularly important in the spontaneously breathing subject as breath to 
breath concentrations may vary considerably. 
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3.7.2 Preconcentration and desorption 
Because most substance concentrations in exhaled breath fall in the nmol/l-pmol range, 
preconcentration is necessary.  This can be achieved by adsorption onto sorbent traps, 
coated fibres[116, 117] or by direct cryofocussation[118].  Variation in the boiling points 
of different VOCs means that adsorbents in sorbent traps have to be carefully selected to 
avoid breakthrough as well as memory effects.  Organic polymers (e.g. Tenax TA)[119], 
activated charcoal[120], different types of graphitized carbon (e.g. Carbopack X), and 
carbon molecular sieves (e.g. Carboxen 1021) have been used[121].  Organic polymers 
are least affected by high water content in the samples but have low breakthrough 
volumes, especially for small hydrocarbons.  In contrast, carbon molecular sieves and 
graphitized carbon have high breakthrough volumes for these compounds.  The downside 
is possible memory effects when these compounds are used as the only adsorption 
material.  Multibed sorbent traps can overcome these problems[121, 122].  For further 
analysis the VOCs must be liberated from the adsorption material.  This can be achieved 
by heating the trap (thermal desorption) or by means of microwave energy. 
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3.7.3 Analysis and detection 
Hydrocarbons in the nmol/l-pmol/l range are usually determined using GC coupled to 
flame ionisation or mass selective detection.  The choice of separation column is crucial.  
Substances such as isopentane may coelute with pentane[123].  As a result mass 
spectrometric analysis has to be applied for the detection of unknown compounds.  The 
high water content of breath samples can affect preconcentration, separation and 
detection of single compounds.  This is a particular problem in mechanically ventilated 
patients who breathe humidified gases. 
  
3.7.4 Normalisation/expression of data 
Problems with this aspect of breath analysis has been one of the major causes of the 
significant variations in results seen in published studies.  The normalization of data by 
the ratio of PCO2 in the sample to end tidal PCO2 is a minimum requirement when mixed 
expiratory and not alveolar samples are taken.  This is necessary to account for the 
dilution of the sample by dead space air.  Because the extent of this dilution cannot be 
quantified and may be variable, the only method to obtain reliable and comparable results 
is the normalisation of samples to alveolar concentration levels[98, 111]. 
 
Exhaled compound concentrations can be affected by physiological factors such as 
cardiac output, minute ventilation and ventilation/perfusion ratio in the lung.  In healthy 
volunteers, these effects may be negligible.  In patients with significant physiological 
dysfunction the effects can be marked.   
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3.8 Breath Markers in disease 
The main disease targets for investigation have been lung diseases, inflammatory and 
malignant processes and specific disease states such as allograft rejection and renal 
failure.  The requirements and problems with breath testing differ depending on the type 
of study undertaken: 
 
In cross sectional studies a control group is compared to a patient or disease group.  
Breath markers are analysed in order to detect qualitative or quantitative differences 
between the two groups.  Attempts are made to find biomarkers specific to the disease in 
question or predictive biomarkers. 
   
In longitudinal studies, disease progression is investigated.  Breath markers are observed 
during the timecourse of a disease or an intervention within a patient group.  Variation of 
results is less of a problem than in cross sectional studies, because each patient can act as 
their own control. 
 
Due to individual differences, concentrations of some volatiles may vary considerably 
even in the healthy state[82].  In spite of this some correlations between clinical 
conditions and breath marker concentrations have been described.    
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3.8.1 Lung Cancer 
Approximately 180,000 people in the USA develop lung cancer every year.  The 5 year 
survival over all is a depressing 14%.  This can be increased to 50% if lung cancer is 
localised at the time of diagnosis and treatment is prompt.  The detection of lung cancer 
at an early stage could be accomplished by breath analysis when useful markers have 
been determined[82].  Studies have been performed in attempts to characterise 
compounds in breath samples from patients with and without lung cancer.  Samples were 
collected with a portable machine in which 10L of breath was passed through a sorbent 
trap containing activated carbon.  VOCs were then thermally desorbed, concentrated by 
two stage cryofocussing and then quantified by GC-MS. 
 
A combination of more than 20 breath VOCs, predominantly alkanes, alkane derivatives, 
o-toluene, analine, and benzene derivatives, along with altered lipid peroxidation activity 
[124-127], was shown to be able to discriminate patients with lung cancer with a 
probability of about 70%.  More work is needed to confirm these findings in the general 
population. 
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3.8.2 Inflammatory Lung Diseases 
Non-invasive monitoring of these conditions including asthma, cystic fibrosis, chronic 
obstructive pulmonary disease, bronchiectasis and interstitial lung diseases can be 
observed by various biomarkers in the breath.  Nitric oxide, carbon monoxide, ammonia, 
and many non-volatile molecules (isoprostanes, leukotrienes, prostaglandins, cytokines, 
products of lipid Peroxidation, nitrite/nitrate, S-nitrosthiols, nitrotyrosine) have been 
measured in breath samples[128].  The analysis of exhaled breath may also be used to 
monitor a course of therapy.  Increased concentrations of 8-isoprostane, hydrogen 
peroxide, nitrite, and 3-nitrotyrosine are found in exhaled breath in inflammatory lung 
diseases.  In addition, increased levels of lipid mediators are found in these conditions, 
with a differential pattern depending on the nature of the disease process[129]. 
 
3.8.3 Nitric Oxide as a Marker of Pneumonia in Ventilated Patients 
Nitric Oxide (NO) has been proposed as a marker of pneumonia in ventilated patients by 
Adrie et al[88].  Nitric Oxide is known to play a vital role in the control of vasomotor 
tone and blood flow in both the systemic and pulmonary circulation[130, 131].  NO is 
synthesised by different forms of nitric oxide synthase (NOS).  A calcium independent 
isoform of NOS, known as inducible NOS (iNOS), can be activated by various cytokines 
and bacterial endotoxin.  This can lead to excess production of NO in many inflammatory 
conditions.  The consequence of this is inappropriate systemic vasodilatation, as seen in 
bacterial sepsis.  Steudel et al.[132] proposed that iNOS is the principal contributor to 
exhaled NO synthesis.  Adrie et al.[88] hypothesised that as inflammation results from 
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infection, which in turn releases NO, exhaled NO levels would be elevated in ventilated 
patients with pneumonia.  NO may therefore act as a marker of pneumonia in these 
patients. 
 
 NO levels were measured using chemoluminescence.  Plasma nitrite and nitrate levels 
were also measured, in order to investigate any correlation between exhaled NO levels 
and plasma levels of nitrite and nitrate.  This was to test the hypothesis that nonspecific 
inflammation could induce iNOS expression specifically in the airway epithelium, which 
would be detected by a rise in NO levels in the nasal passages, or non-specifically as seen 
by an increase in plasma nitrite levels.  NO contamination from inhaled gases was 
excluded by the use of specific filters. 
 
Forty nine patients admitted consecutively within 72 hours to the intensive care unit were 
included.  Twenty one of these patients were diagnosed as having pneumonia based on a 
clinical scoring system similar to CPIS.  Significantly higher tracheal NO levels were 
observed in those diagnosed with pneumonia.  The researchers proposed an end-
expiratory tracheal threshold level of 5 ppb and a nasal NO threshold of 500 ppb as 
definitive for a diagnosis of pneumonia.  Nasal NO levels were also elevated in this 
group, suggesting the presence of a generalised airway epithelium response rather than a 
specific distal airway response.  The threshold levels established were then validated on a 
second group of 60 consecutive patients admitted to the intensive care unit. 
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This hypothesis was further supported by the finding of an inverse correlation between 
plasma NOx levels and exhaled NO levels in patients with pneumonia.  This was not seen 
in the total population.  The authors argue that this could be specific for pneumonia as 
this was not seen in patients with other causes of sepsis.  Delen et al.[133]  showed that 
exhaled NO was elevated in chronic bronchitis but not in patients with Chronic 
Obstructive Pulmonary Disease (COPD).  Exhaled levels of NO have been found in 
patients with asthma[134, 135] further supporting its role as a marker of airway 
inflammation. 
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3.8.4 Oxidative stress 
Lipid peroxidation is a free radical mediated degradative process which involves 
polyunsaturated fatty acids in cells.  This leads to the formation of lipid hydro peroxides, 
whose decomposition process gives rise to a wide variety of carbonyl secondary 
oxidation products[136, 137].  Malondialdehyde, one of the major products, has been 
found to be elevated under various conditions of oxidative stress, where reactive oxygen 
and nitrogen species play important roles. 
 
Cancer has been shown to be accompanied by the increased production of oxygen free 
radicals that degrade membranes by lipid peroxidation, releasing VOCs that are seen in 
the breath.  Heart transplant rejection is also accompanied by increased oxygen free 
radical activity, and breath VOC analysis may be able to detect markers of rejection.  
Increased levels of ethane and pentane have been related to oxidative stress in breast 
cancer[138], heart transplant rejection[139] and bronchial asthma[140] although they are 
of little value for diagnostic purposes owing to the lack of sensitivity and specificity.  
Methylated alkanes have also been proposed as markers of oxidative stress[141].         
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3.9 Selected Ion Flow tube- Mass Spectrometry (SIFT-MS) 
Selected ion flow tube mass spectrometry (SIFT-MS) was conceived in 1976 by Adams 
& Smith[142].  It provides the opportunity for real time detection and quantification of 
the trace gases present in exhaled breath.   GC-MS has been used to perform analysis on 
exhaled breath and detect compounds at parts per billion (ppb) and even parts per trillion 
(ppt) levels for several decades.  However, it requires the collection of the gases of 
interest onto specialised adsorbtion or cryogenic traps.  This means that GC-MS cannot 
be regarded as real time monitoring. 
 
The other disadvantages of GC-MS are as follows: 
 
(i) The fragmentation pattern of each component of the gas mixture must be 
known when the electron ionisation method is used.  This is generally the case 
in GC-MS. 
(ii) The instruments have to be calibrated for each trace gas to achieve accurate 
quantification. 
(iii) Low molecular weight compounds such as formaldehyde and ammonia are 
not readily detected by GC-MS[143, 144]. 
 
SIFT-MS presents a real time breath analytical tool which does not suffer the drawbacks 
listed above. 
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3.9.1 How does SIFT-MS work? 
A detailed description of the physics and chemistry underlying this technology is beyond 
the scope of this introduction but can be found in Smith & Spanel 2004[145].  A basic 
description follows: 
 
The trace gases in the breath sample are ionised using a precursor ion species (either 
H30
+
, NO
+ 
or 02
+
 are used depending on the trace gas compounds to be analysed) chosen 
from the mixture of ion species formed in a microwave discharge by a quadropole mass 
filter.  The ions are injected into a fast flowing inert carrier gas (usually helium at a 
pressure of ~ 100Pa) through a Venturi-type orifice (diameter typically 1-2mm).  The 
breath sample is introduced into the entry port of the SIFT-MS machine via a mouthpiece 
and then into the carrier gas at a known flow rate through a heated calibrated capillary.  
The precursor ions are thermalised to the carrier gas temperature (usually 300 K) by 
multiple collisions with the helium atoms before reacting with the trace gases in the 
breath sample.  It is the ratio of the count rates of the product ions to the precursor ions 
that is essential parameter in the quantification of the particular trace gas compounds. 
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Fig 3.6 Schematic representation of the SIFT-MS instrumentation showing the main 
components.  This diagram shows H3O
+ 
as the precursor ions. 
 
 
3.10 Pattern Recognition and Statistical Methods 
Interpretation of the sensor data and the characteristics of individual odour patterns are 
critical to the functioning of an Enose.  During odour classification, new sensor data is 
compared against a set of known volatile profiles.  These form the “odour memory”.  A 
number of statistical methods have been employed in order to facilitate data reduction in 
order to study complex volatile mixtures.  In these complex mixtures overlapping sensor 
sensitivities are partially correlated.  In this piece of research we have focused on the use 
of Principal Components Analysis (PCA) and Linear Discriminant Analysis (LDA). 
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3.10.1 Principle Components Analysis (PCA) 
(from http://home.ubalt.edu/ntsbarsh/stat-data/Topics.htm) 
“Multivariate analysis is a branch of statistics involving the consideration of objects on 
each of which are observed the values of a number of variables. Multivariate techniques 
are used across the whole range of fields of statistical application: in medicine, physical 
and biological sciences, economics and social science, and of course in many industrial 
and commercial applications.  
 
Principal components analysis is used for exploring data to reduce the dimension. 
Generally, PCA seeks to represent n correlated random variables by a reduced set of 
uncorrelated variables, which are obtained by transformation of the original set onto an 
appropriate subspace. The uncorrelated variables are chosen to be a good linear 
combination of the original variables, in terms of explaining maximal variance and 
orthogonal directions in the data. Two closely related techniques, principal component 
analysis and factor analysis, are used to reduce the dimensionality of multivariate data. In 
these techniques correlations and interactions among the variables are summarized in 
terms of a small number of underlying factors. The methods rapidly identify key 
variables or groups of variables that control the system under study. The resulting 
dimension reduction also permits graphical representation of the data so that significant 
relationships among observations or samples can be identified.  
. 
76 
 
 
 
The main applications of factor analytic techniques are: 
 
1. To reduce the number of variables and 
2. To detect structure in the relationships between variables, that is to classify 
variables. 
 
Therefore, factor analysis is applied as a data reduction or structure detection method. 
Confirmatory factor analysis allows you to test specific hypotheses about the factor 
structure for a set of variables, in one or several samples. 
 
Correspondence analysis is a descriptive/ exploratory technique designed to analyse two-
way and multi-way tables containing some measure of correspondence between the rows 
and columns.  These results provide information which is similar in nature to those 
produced by factor analysis techniques, and they allow one to explore the structure of 
categorical variables included in the table. 
 
Combining Two Variables into a Single Factor.  One can summarise the correlation 
between two variables in a scatterplot.  A regression line can then be fitted that represents 
the “best” summary of the linear relationship between the two variables.  If we could 
define a variable that would approximate the regression line in such plot, then that 
variable would capture most of the “essence” of the two items.  Subjects‟ single scores on 
that new factor, represented by the regression line, could then be used in future data 
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analyses to represent that essence of the two items.  In a sense we have reduced the two 
variables into one factor.  Note that the new factor is a linear combination of the two 
variables. 
 
Principal Components Analysis.  The example above, combining two correlated variables 
into one factor, illustrates the basic idea of principle component analysis.  If we extend 
the two-variable example to multiple variables, then the computations become more 
involved, but the basic principle of expressing two or more variables by a single factor 
remains the same.   
 
Extracting Principle Components.  The extraction of principle components amounts to a 
variance maximising rotation of the original variable space.  For example in a scatterplot 
we can think of the regression line as the original x-axis, rotated so that it approximates 
the regression line.  This type of rotation is called variance maximising because the goal 
of the rotation is to maximise the variability of the “new” variable (factor), while 
minimising the variance around the new variable. 
 
Multiple orthogonal factors:  After we have found the line on which the variance is 
maximal, there remains some variability around this line.  In PCA, after the first factor 
has been extracted, that is, after the first line has been drawn through the data, we 
continue and define another line that maximises the remaining variability, and so on.  In 
this manner, consecutive factors are extracted.  Because each consecutive factor is 
defined to maximise the variability that is not captured by the preceding factor, 
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consecutive factors are independent of each other.  Put another way, consecutive factors 
are uncorrelated or orthogonal to each other. 
 
How many factors to extract?  As we extract consecutive factors, they account for less 
and less variability.  The decision on when to stop extracting factors basically depends on 
when there is only very little “random” variability left.  The nature of this decision is 
arbitrary; however, various guidelines have been developed.”    
 
 
3.10.2 Linear Discriminant Analysis (LDA) 
(http://home.ubalt.edu/ntsbarsh/stat-data/Topics.htm) 
“Linear discriminant analysis (LDA) and the related Fisher's linear discriminant are used 
in statistics to find the linear combination of features which best separate two or more 
classes of object or event. The resulting combinations may be used as a linear classifier, 
or more commonly in dimensionality reduction before later classification. 
 
LDA is closely related to ANOVA (analysis of variance) and regression analysis, which 
also attempt to express one dependent variable as a linear combination of other features 
or measurements. In the other two methods however, the dependent variable is a 
numerical quantity, while for LDA it is a categorical variable (i.e. the class label). 
 
LDA is also closely related to principal component analysis (PCA) and factor analysis in 
that both look for linear combinations of variables which best explain the data. LDA 
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explicitly attempts to model the difference between the classes of data. PCA on the other 
hand does not take into account any difference in class, and factor analysis builds the 
feature combinations based on differences rather than similarities. Discriminant analysis 
is also different from factor analysis in that it is not an interdependence technique: a 
distinction between independent variables and dependent variables (also called criterion 
variables) must be made. 
 
Unlike PCA, LDA requires information as to how the variables are classified.  LDA 
involves finding a Linear Discriminant Function that maximises the distance between two 
groups whilst minimising the distance between the members of each group.  The LDF 
can therefore be thought of as a vector or direction. 
 
The purpose of LDA is to classify objects into one of two or more groups based on a set 
of features that describe the objects.  In general, we assign an object to one of a number 
of predetermined groups based on observations made on the object. 
 
Note that the groups are known or predetermined and do not have order (i.e. nominal 
scale).  The classification problem gives several objects with a set of features measured 
from those objects.  We are looking for two things: 
 
1. Which set of features can best determine group membership of the object? 
2. What is the classification rule or model to best separate those groups?”  
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During the analysis of the data presented in this research we have used PCA, LDA and 
PCA fed LDA for the classification of Enose data. 
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Chapter 4 Methods 
This section will describe the general methods employed in the design and execution of 
this study.  Detailed methods for each of the individual experiments are contained in the 
relevant sections. 
 
Approval was gained from the Gloucestershire Local Research Ethics Committee for all 
the research experiments described in this thesis.  The issue of gaining informed consent 
from patients receiving mechanical ventilation is a difficult area.  The majority of these 
patients are unable to give informed consent as they are either unconscious or sedated to 
allow intubation and ventilation.  UK law states that no adult can give consent for 
medical treatment on behalf of another adult.  The ethics committee stated that where a 
close family member was available we were to gain assent (not consent) from that family 
member as an indication of the patient‟s wishes.  Should the patient then recover and be 
able to give informed consent, this was gained retrospectively.  If the patient 
subsequently refused to be included in the study, their samples and study data were to be 
confidentially destroyed.  This scenario did not arise during the course of this study. 
 
BAL samples and breath samples collected with the Breathotron were collected from the 
same patient in one sampling episode.  Breath samples were collected prior to BAL 
samples in order to avoid the potential for the normal saline used during the BAL 
sampling to contaminate the breath samples. 
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BAL sampling was performed by instilling 20ml of sterile normal saline solution into the 
respiratory tract of the patient and aspirating back as much of the fluid as possible.  The 
recovered fluid was then divided into two equal aliquots; one of which was sent for 
standard microbiological analysis and the other was sent to Cranfield for Enose analysis.  
Enose analysis is performed in an attempt to discriminate patients with evidence of 
microbiological growth in the BAL sample from those without.  We compare this 
analysis with accepted microbiological methods.  Further details can be found in Chapter 
5. 
 
The breath samples were collected by passing a fixed volume of breath (total of 5 litres) 
through a specially designed sorbent trap.  This trap collects and pre-concentrates volatile 
compounds in the breath.  The compounds are then analysed by means of a GC-MS 
machine in an attempt to identify the many individual compounds present in a single 
breath sample.  This was undertaken in order to investigate whether we could identify 
compounds in breath that may act as biomarkers of VAP.  More detail on this process can 
be found in Chapter 6. 
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At the same time that breath samples are being collected as described above, the 
Breathotron also uses a single MMOS sensor to analyse the breath being collected.  This 
is an attempt at using a single sensor Enose type approach to breath analysis instead of 
employing a sensor array as found in most commercial Enose devices.  If a single sensor 
has the ability to discriminate breath samples with acceptable accuracy then this could 
mean a smaller and cheaper device could be developed for near patient testing.  More 
details can be found in Chapter 7. 
 
Patients were identified in the Intensive Care Units (ICU) at Cheltenham General and 
Gloucestershire Royal Hospitals.  Patients who had been receiving mechanical ventilation 
for a minimum of 48 hours were identified.  The reason for ventilation was not 
considered important.  The first samples were collected as close to day 3 of ventilation as 
possible.  Samples were then repeated on a Monday, Wednesday and Friday until the 
patient no longer required ventilation. 
 
The Breathotron was connected to the exhaust arm of the ventilator circuit and a heat and 
moisture exchange (HME) filter was placed in the circuit between the patient and the 
Breathotron.  This was done to prevent contamination of the Breathotron by respiratory 
secretions which could have the potential to cross infect study participants.  The filters 
are designed to block micro-organisms but it was not felt that they should trap VOC‟s 
and have a detrimental effect on the breath sampling. 
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A patient data collection proforma was completed for every sampling episode.  An 
example is shown overleaf.   
 
87 
 
 
 
Ventilator Associated Pneumonia: Tandem Breath Analyser Vs. Bronchoalveolar 
Lavage 
 
Patient Data Collection Sheet 
 
 
 
Please complete one of these forms EACH time a patient undergoes BAL.  
Study number:     Trap number: 
Date sampling performed: 
 
 
 
Current diagnosis (reason for ventilation): 
 
 
Drugs at time of sampling (inc. sedation etc.): 
Antibiotic therapy within last 48h (inc. prophylactic in theatre): 
 
 
VAP clinical diagnosis criteria 
 
 
 
     PAS  LABEL 
 
 
 
88 
 
 
Temp °C 
>or equal to 36.5 and <or equal to 38.4 = 0 points 
>or equal to 38.5 and <or equal to 38.9 = 1 point 
>or equal to 39 and <or equal to 36.0 = 2points 
 
White cell count/mm
3 
>or equal to 4000 and <or equal to 11000 = 0 points 
<4000 or >11000    = 1 point 
 
Tracheal Secretions 
No secretions     = 0 points 
Non purulent secretions   = 1 point 
Purulent secretions    = 2 points  
 
Oxygenation: PaO2/FiO2, KPa  
>31.6 or ARDS     = 0 points 
< or equal to 31.6 and no ARDS   = 2 points 
89 
 
 
    
CXR findings 
 
No infiltrates      = 0 points 
Diffuse/patchy infiltrates   = 1 point 
Localised infiltrates    = 2 points 
 
Progression of infiltrates 
 
No radiographic progression   = 0 points 
Radiographic progression   = 2 points 
(after exclusion of CHF and ARDS) 
 
Culture of tracheal aspirates 
 
Pathogenic bacteria cultured in rare or light growth/no growth = 0 points 
Pathogenic bacteria cultured in moderate/heavy growth  = 1 point 
Pathogenic bacteria on Gram stain     =  ADD 1 point 
 
TOTAL SCORE:    /12 (Score 6 or more significant) 
  
Adapted from Pugin et al.  1991 
CHF is congestive heart failure. 
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Chapter 5 
Enose Analysis of BAL Samples for the 
Investigation of VAP
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As has been discussed in the introduction to this work, there is no accepted gold standard 
test for the diagnosis of VAP.  All of the investigations discussed have their advantages 
and disadvantages.  This lack of a gold standard clearly has implications when 
investigating the use of a novel technology for the diagnosis of VAP.  In this study we 
have decided to use quantitative cultures performed on blind BAL samples as our chosen 
microbiological technique for the diagnosis of VAP.  The use of this technique is 
widespread and accepted within the medical community. 
 
5.1 Bronchoscopic versus Nonbronchoscopic techniques for BAL sampling 
Bronchoscopy provides direct access to the lower airways for sampling bronchial and 
parenchymal tissues directly at the site of inflammation.  Proper selection of the correct 
sampling site can be technically challenging.  The majority of intubated patients have 
purulent looking secretions, and the secretions first seen may represent those aspirated 
from another site into gravity-dependent airways.  Secretions from the upper airways can 
also be aspirated around the endotracheal tube.  Usually the sampling area is selected 
based on chest x-ray appearances or the segment visualised during bronchoscopy as 
having purulent secretions[146].  In cases where there are diffuse pulmonary infiltrates or 
minimal chest x-ray changes in a previously abnormal chest x-ray, selecting the correct 
site to sample can be challenging.  In cases where no clear sampling site exists, and 
because autopsy studies show that VAP frequently involves the right lower lobe, this area 
should be sampled[147].  There is no convincing evidence that sampling from multiple 
sites is more accurate than single specimens for diagnosing VAP.[148] 
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A variety of nonbronchoscopic sampling techniques have been described in the literature, 
results have been comparable to those obtained using fibreoptic bronchoscopy [149].  In 
comparison with protected specimen brush (PSB) and/or bronchoscopic BAL, non 
bronchoscopic techniques are less invasive, can be performed by clinicians not trained to 
perform bronchoscopy, have lower initial costs than bronchoscopy, avoid potential 
contamination via the bronchoscopic channel, are associated with less compromise of gas 
exchange during the procedure, and can be performed in patients intubated with small 
endotracheal tubes. 
 
Disadvantages of the blind sampling technique include the potential sampling errors 
inherent to a blind technique and the inability to visualise the airways directly.  Although 
autopsy studies indicate that pneumonia in ventilated patients has often spread throughout 
the lungs, several studies on patients with VAP contradict those findings, as some 
patients had sterile PSB cultures from the non-involved lung [148, 150].  Although the 
authors of most studies concluded that the sensitivities of nonbronchoscopic and 
bronchoscopic techniques were similar, the overall concordance was only 80%.  This 
demonstrates that in some patients the diagnosis could be missed by the blind technique. 
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In our units there was no agreed policy for the diagnosis of VAP in existence.  After 
discussion with senior ICU clinicians and reviewing the literature we decided to use blind 
BAL sampling as our gold standard with which to compare the Enose.  The decision was 
based on ease of use and low cost. 
 
5.2 BAL Technique 
We have adopted the method of blind BAL sampling adopted by Garrard et al.[151].  The 
patient was ventilated with 100% Oxygen prior to sampling.  The patient was positioned 
30 degrees head-up and disconnected from the ventilator circuit.  A 14 Fr suction catheter 
was then introduced down the endotracheal or tracheostomy tube into the bronchial tree 
until for it could be advanced no further.  20 ml of sterile normal saline was then injected 
through the catheter and immediately aspirated back into the syringe.  Care was taken to 
stop aspiration before the tip of the suction catheter was withdrawn into the endotracheal 
or tracheostomy tube.  The sample was divided in two and placed in sterile sample 
containers for microbiological and Enose analysis. Quantitative microbiological culture 
was performed according to the standard hospital protocol. 
 
The sample for Enose analysis was stored at 4°C in a controlled temperature fridge.  
Samples were collected and then sent via next day delivery post to Cranfield University 
where they were again stored at 4°C until they were analysed with the Enose.  This 
method of collection and storage may have adversely affected our results and will be 
discussed later. 
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The samples for analysis by the microbiology department at Gloucestershire Hospitals 
NHS Foundation Trust were processed according to the following pre-agreed protocol: 
  
3.8ml sterile saline was pipetted into one universal container, labelled A.  9ml sterile 
saline was pipetted into a second universal container, labelled B.  The BAL sample was 
vortex mixed.  Using a sterile serological pipette 0.2ml of the sample was transferred to 
container A (1:20 dilution).  Container A was vortex mixed.  Using a sterile serological 
pipette 1.0ml from container A was transferred to container B (1:200 dilution). Container 
B was vortex mixed.  50 microlitres from both containers was inoculated onto the various 
media shown below, spread with a sterile loop and incubated as shown. 
 
 
Media Conditions Incubation Time 
Blood Agar 37°C, 5% CO2 2 days 
Chocolate Agar 37°C, 5% CO2 2 days 
FAA 37°C, ANO2 2 days 
CLED 37°C, Air 1 day 
Sabourad 30°C, Air 
37°C, Air 
5 days 
5 days 
Table 5.1 Culture media and parameters. 
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The remaining sample was stored in a - 20°C freezer.  After incubation the plates were 
read and the degree of growth of all significant organisms was recorded.  All significant 
organisms were identified and standard laboratory sensitivity testing was performed.  All 
significant isolates were stored on beads in the -20°C freezer. 
 
5.3 Preparation of samples for headspace analysis 
The clinical samples were stored in a 4°C cold room and allowed to warm to room 
temperature.  The samples were then pipetted into 25ml glass vials and allowed to 
equilibrate at room temperature for 1 hour.  The headspace was then analysed in a 
random order using an NST 3320 Enose (Applied Sensor, Sweden) comprising a hybrid 
sensor array. 
 
For the microbial species which had been isolated from the clinical samples, the isolates 
were maintained on nutrient agar plates.  One colony per species was inoculated in 10ml 
sterile nutrient broth (LabM) and incubated for 4 hours at 37°C in a rotary shaker at 
100rpm.  Thereafter 100 microlitres of each microbial suspension was transferred into a 
fresh 10ml sterile nutrient broth and incubated for 18hours at 37°C in a rotary shaker at 
100rpm.  Subsequently, 5ml from each suspension was transferred into 25ml glass vials 
and left for 1 hour at 37°C for headspace generation.  Uninoculated nutrient broth was 
used as a control and five replicates per treatment were analysed in a random order using 
the Enose.  These studies were repeated at least twice. 
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The response generated by the Enose sensors in the form of normalised, mean-centred 
data were analysed using Matlab 7.2(MathWorks Inc., Natick MA, USA).  The response 
is defined as the change in resistance of each of the 24 individual sensors in the detection 
array to the adsorption and desorption of VOC‟s in the headspace of the sample being 
analysed.  The Enose used in this study is a NST 3320 manufactured by Applied Sensor 
of Sweden.  It uses a hybrid metal oxide semiconductor sensor array. 
 
5.4 Metal Oxide Sensors 
The following description is taken from the Handbook of Machine Olfaction[92]. 
“Metal oxides such as SnO2, ZnO, Fe2O3 and WO3 are intrinsically n-type 
semiconductors.  At temperatures of 200-500 °C, these respond to reducible gases such as 
H2, CH4, CO, C2H5, or H2S and increase their conductivity.  In the atmosphere, some 
oxygen atoms are adsorbed onto the surface of these semiconductors to trap free electrons 
from the semiconductor, and consequently a highly resistive layer is produced in the 
vicinity of the semiconductor surface.  The adsorption of oxygen atoms on the 
semiconductor surface and at grain boundaries of polycrystalline semiconductors creates 
an electrical-double layer that acts as the scattering centre for conducting electrons.  The 
consequent increase in free electrons and decrease in scattering centres results in an 
increase in conductivity. 
 
The reaction between gases and surface oxygen will vary depending on the operating 
temperature of the sensor and the activity of the sensor materials.  The increasing 
sensitivity and selectivity of the sensors for exposure to gases can be realized by 
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incorporating a small amount of impurities and catalytic metal additives such as 
palladium or platinum.  The impurities act as extrinsic donors (or acceptors) and, 
consequently, controlling the doped amount of impurities can change the conductivity of 
the sensors.  Doping of the catalytic metal to the sensor or coating with thin catalytic 
metal film of the sensor surface changes the selectivity of the sensor. 
 
The most widely used semiconducting material as a gas sensor is Sn02 doped with small 
amounts of impurities and catalytic metal additives.  By changing the choice of impurity 
and catalyst and operating conditions such as temperature, many types of gas conductors 
exhibit relatively poor selectivity for gases and remain responsive to many kinds of 
combustible gases.” 
 
5.4.1 AppliedSensor Technologies MOS Sensors (from www.appliedsensor.com) 
The following description of the Applied Sensor technologies is taken directly from 
product information found on the company website: 
 
“AppliedSensor metal oxide semiconductor (MOS) sensors use metal oxide-based 
sensing thick films deposited onto a Si-micro-machined substrate (micro sensors). 
The substrate contains electrodes that measure the resistance of the sensing layer, 
and a heater that heats the sensing layer to 200°C to 400°C. 
The sensor responds to changes in the composition of the ambient atmosphere 
with a change in the resistance of the sensing layer. A large number of toxic and 
explosive gases can be detected, even at very low concentrations. 
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Micro sensors operate in wide ambient temperature 
MOS sensors detect a wide range of gases, including CO, NO2, NH3, H2S, CH4, 
and a wide variety of volatile organic compounds (VOCs). These maintenance-free 
sensors show high sensitivity, good stability, long lifetime, and short response/ 
recovery times. They can be operated in a wide ambient temperature range (-40°C 
to +70°C) and a humidity range of 0 to 100% RH without condensation. 
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5.4.2 Chemical Principle 
The sensing layer is a porous thick film of polycrystalline SnO2. In normal ambient air, 
oxygen and water vapour-related species are adsorbed at the surface of the SnO2 
grains. The sensing of target gases takes place as follows: 
 
For reducing gases such as CO or H2, a reaction takes place with the pre-adsorbed 
oxygen and water vapour-related species which decreases the resistance of the sensor. 
For oxidizing gases such as NO2 and O3, the resistance increases. The magnitude of 
the changes depends on the microstructure and composition/doping of the base 
material, on the morphology and geometrical characteristics of the sensing layer and 
substrate, as well as on the temperature at which the sensing takes place. Alterations 
of these parameters allow for the tuning of the sensitivity towards different gases or 
classes of gases.  This is illustrated in the figure below: 
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Figure 5.1 Sketch of an MOS sensor illustrating the detection principle. The resistance of 
the sensing layer changes when molecules react on the surface. 
 
5.4.3 Transducer Principle 
The changes in composition of the ambient atmosphere will determine changes in 
resistance of the sensing layers. In practice, the relationship between sensor resistance 
and concentration of the target gas usually follows a power law. Over a large range of 
concentrations, it can be described by: 
R =~ K • c±n 
“c” is the concentration of the target gas, “K” is a measurement constant, and “n” 
has values between 0.3 and 0.8. The positive sign is used for oxidizing gases and the 
negative sign for reducing gases. 
 
101 
 
 
5.4.4 Typical Response Curves 
Figures 5.2 and 5.3 show the typical behaviour for a thick-film MOS sensor when 
exposed to a series of CO pulses. The sensor resistance drops very quickly immediately 
after CO exposure, and after removal of CO from the ambient atmosphere, the sensor 
resistance will recover to its original value after a short time. The speed of response 
and recovery will vary according to the operation temperature, the type of sensing 
layer, and the gases involved”. 
 
Figure 5.2 Response of a thick-film MOS sensor to CO. 
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Figure 5.3 CO concentration vs. sensor signal for a thick-film MOS sensor. 
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5.5 Enose and BAL analysis 
The exploration of odour sensing technologies as a method of identifying infections or 
diseases such as cancer has gathered pace in recent years.  It has the potential to offer a 
rapid, near patient and non invasive method for diagnosis.  It has long been known that 
certain diseases have characteristic odours, from the pear drop smell of acetone on the 
breath of diabetics to the fishy smell of liver disease.  These odours are often difficult for 
the human nose to detect, especially at low concentrations.  We are now turning to 
modern technology as a way of detecting these odours and measuring them in a 
scientifically acceptable and reproducible way.  The electronic nose is a technology 
capable of detecting the volatile fingerprints of disease and infection.  Enose technology 
has been successfully used to discriminate between various Mycobacterial isolates in 
humans[86] and in animals[152].  In vitro studies have also been carried out on bacteria 
responsible for eye infections [153]. 
 
As we have discussed previously, VAP is one of the most common and significant 
hospital acquired infections.  Its high mortality rate and difficult diagnosis combined with 
the lack of a gold standard diagnostic test, makes it an attractive target for Enose 
diagnosis.  This study explored the potential of volatile fingerprints generated by various 
pathogenic microbial species not only in vitro but also those present within clinical 
samples taken from ventilated patients on the Intensive Care Unit.  We also attempted to 
correlate the microbiology culture results with the Enose responses for the clinical 
samples. 
104 
 
 
 
5.6 Materials and Methods 
5.6.1 Collection of clinical samples 
The patients recruited for this study were mechanically ventilated for more than 72 hours, 
on the Intensive Care Units at Gloucestershire Royal or Cheltenham General hospitals.  
The control group were patients ventilated for less than 24 hours for any reason other 
than pneumonia.  All patients underwent a blind bronchoalveolar lavage (BAL) 
performed by a trained clinician on day three and then every Monday, Wednesday and 
Friday until ventilation was discontinued.   Exclusion criteria were lack of patient consent 
to sample collection and an inspired oxygen concentration of more than 80%.  Patients 
requiring an inspired oxygen concentration of more than 80% were felt to be too oxygen 
dependent to tolerate BAL sampling safely.   Control samples were collected from 
patients mechanically ventilated following elective surgery within 24 hours of admission 
to the ICU with no evidence of pulmonary problems.  The control group had one off 
sampling performed.  For a statistical power of 80%, with 5% significance, a sample size 
of 100 samples was calculated assuming an incidence of VAP of 25% within our patient 
population. Ethical approval is detailed in Appendix 1. 
 
The blind BAL involved introducing 20ml of sterile normal saline into the lungs via a 
sterile 14 gauge suction catheter attached to a 20ml syringe.  Prior to injection the patient 
was pre-oxygenated with 100% Oxygen and then disconnected from the ventilator circuit.  
The catheter was introduced into the bronchial tree via the endotracheal tube until it could 
be advanced no further.  The sterile saline was then injected and immediately aspirated 
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back, care was taken not to aspirate when the tip of the catheter was inside the 
endotracheal tube in order to minimise the risk of contamination from microorganisms 
colonising the tube.  The aspirate was collected in sterile containers and divided in two; 
one sample being sent for standard microbiological culture in the hospital lab and the 
second sample posted to the University for headspace analysis (blind study).  The 
samples were stored at 4°C prior to analysis.   A total of 102 samples were collected over 
a period of 26 months (April 2006 to June 2008).  
 
5.6.2 Microbial isolates 
A total of 16 microbial organisms (including Staphylococcus, Streptococcus, MRSA, 
Proteus, Pseudomonas, Klebsiella, Enterobacter and Candida) were isolated from the 
study patients.  The isolates were provided by the microbiology lab at Cheltenham 
General Hospital who had processed the BAL samples for the study.  These were 
maintained on nutrient agar (LabM) at 37°C for this study and stored at 4°C until 
required. 
 
5.6.3 Headspace analysis 
The clinical samples were removed for the cold room and allowed to thaw at room 
temperature.  Following this, the samples were pipette into 25ml glass vials and set aside 
for one hour at room temperature to equilibrate.  The headspace was then analysed in a 
random order using the NST 3320 Enose (Applied Sensor, Sweden) comprising a hybrid 
metal oxide semiconductor sensor array of 24 individual sensors. 
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For the microbial species, the isolates were maintained on nutrient agar plates.  One 
colony per species was initially inoculated in 10ml sterile nutrient broth (LabM) and 
incubated for four hours at 37°C in a rotary shaker at 100rpm.  Thereafter 100 microlitres 
of each microbial suspension was transferred into fresh 10ml sterile nutrient broth and 
incubated for 18 hours at 37°C in a rotary shaker at 100rpm.  Subsequently, 5ml from 
each suspension (approximately 10
8
 and 10
6 
cfu ml
-1
 for the bacterial and yeast species 
respectively) was transferred into 25ml glass vials, set aside for one hour at 37°C for 
headspace generation.  Uninoculated nutrient broth was used as a control and five 
replicates per treatment were analysed in a random order using the Enose.  These studies 
were repeated at least twice. 
 
5.6.4 Data analysis 
The responses generated by the Enose sensors, in the form of normalised, mean centred 
data for the response parameter, were analysed by Matlab 7.2 (Mathworks Inc.).  PCA 
was used as a data reduction technique to explore the variance in the dataset, and fed into 
LDA to correlate Enose response with the findings of BAL sample cultures.  The samples 
are assigned to one of a number of predetermined groups based on observations made 
about the sample.  Due to the sample size, leave one out cross validation was used to 
evaluate how the results would translate to an independent data set.   In the case of the 
clinical samples, the PCA scores were analysed and the results were then correlated to the 
findings obtained from microbiological analysis on the patient‟s BAL samples.  Patient 
anonymity was preserved at all times.  All analysis and correlation was performed using 
patient study numbers.  The same analysis technique was applied to the BAL samples 
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from patients and to the model constructed using species grown in culture media from the 
bacterial slopes. 
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5.7 Results 
5.7.1 Discrimination of the microbial isolates 
One hundred and two samples were obtained from 44 patients and 6 samples from 6 
control subjects (1 control subject subsequently became a patient after being ventilated 
for more than 72 hours).  There were 32 males and 18 females.  Full details of the 
patients, control subjects and the organisms isolated can be found in Tables 5.2, 5.3 and 
5.4.  A summary of the types of microbiological growth is shown in Table 5.3, it can be 
seen that 12 species were isolated. 
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Patient Sample 
Date 
Sex Age Growth Type and 
cfu/ml 
Antimicrobial therapy in 
previous 48h 
1 28/04/2006 M 57  Levofloxacin, Vancomycin 
1 01/05/2006     
1 03/05/2006     
1 08/05/2006     
1 10/05/2006   Candida sp^3  
2 28/04/2006 M 45 Staphylococcus 
sp.^3 and 
Candida^4 
Clindamycin, Levofloxacin, 
Benzylpenicillin 
3 28/04/2006 M 76 Streptococcus sp.^3 Flucloxacillin, Clindamycin 
4 03/05/2006 M 79 Staphylococcus 
sp.^3 
Vancomycin, Rifampacin 
4 05/05/2006     
5 08/05/2006 M 65  Levofloxacin, Teicoplanin 
5 10/05/2006     
6 31/05/2006 F 38  Tazocin, Fluconazole 
7 02/06/2006 F 72  Teicoplanin, Tazocin 
8 09/06/2006 M 41  Fluconazole 
8 12/06/2006     
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Patient Sample 
Date 
Sex Age Growth Type and 
cfu/ml 
Antimicrobial therapy in 
previous 48h 
9 03/07/2006 M 36  Clarithromycin, Meropenem, 
Teicoplanin, Fluconazole 
9 05/07/2006     
9 08/07/2006   Candida sp.^3  
9 10/07/2006     
10 10/07/2006 F 68 Candida sp.^3 and 
Pseudomonas sp.^3  
Ciprofloxacin, Amoxicillin 
11 11/07/2006 M 56  Tazocin 
11 13/07/2006   Streptococcus sp 
(x2)^3, Proteus 
sp.^3 
Tazocin 
11 14/07/2006   Streptococcus sp.^3 Amoxicillin 
11 17/07/2006    Vancomycin, Levofloxacin 
12 28/07/2006 F 61  Levofloxacin, Metronidazole, 
Fluconazole 
13 31/07/2006 F 66  Levofloxacin, Ceftriaxone 
14 15/08/2006 F 76  Ceftriaxone 
14 16/08/2006    Ceftriaxone 
14 18/08/2006   Staphylococcus 
sp.^3 
Ceftriaxone 
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Patient Sample 
Date 
Sex Age Growth Type and 
cfu/ml 
Antimicrobial therapy in 
previous 48h 
15 16/08/2006 M 52 Klebsiella 
pneumoniae^3 
Tazocin, Clarithromycin 
15 18/08/2006   Klebsiella 
oxytoca^3 
Tazocin 
15 21/08/2006    Tazocin, Levofloxacin 
15 23/08/2006   Klebsiella sp.^3, 
Staphylococcus 
sp.^3, Candida 
sp.^3, Aerococcus 
sp.^3 
Tazocin, Teicoplanin 
15 25/08/2006   Candida sp.^3, 
Enterobacter 
sp.(x2)^3,  
Tazocin, Teicoplanin 
16 24/08/2006 F 60 Candida albicans^3 Meropenem, Metronidazole 
16 25/08/2006   Candida sp.^3  
16 01/09/2006   Candida albicans^3 Meropenem, Metronidazole, 
Teicoplanin, Fluconazole 
16 04/09/2006    Meropenem, Metronidazole, 
Teicoplanin, Fluconazole 
16 05/09/2006   Stenotrophomonas Meropenem, Teicoplanin 
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maltophilia^5 
Patient Sample 
Date 
Sex Age Growth Type and 
cfu/ml 
Antimicrobial therapy in 
previous 48h 
17 09/10/2006 M 67  Levofloxacin, Teicoplanin, 
Metronidazole, Fluconazole 
18 09/10/2006 M 42 Staphylococcus 
sp.^3 
Metronidazole, Ciprofloxacin, 
Fluconazole 
18 11/10/2006   Staphylococcus 
sp.^3 
Metronidazole, Ciprofloxacin, 
Fluconazole 
18 13/10/2006   MRSA^5 Metronidazole, Ciprofloxacin, 
Fluconazole 
19 09/10/2006 F 84  Cefuroxime, Metronidazole 
19 11/10/2006     
19 13/10/2006    Erythromycin, Tazocin, 
Teicoplanin, Fluconazole 
19 23/10/2006    Teicoplanin 
20 11/10/2006 F 76 Candida albicans^3 Vancomycin, Imipenem 
20 13/10/2006    Vancomycin, Imipenem 
21 06/11/2006 M 39  Vancomycin, 
Meropenem,Clarithromycin 
21 08/11/2006   Staphylococcus 
sp.^3 
Vancomycin, 
Meropenem,Clarithromycin 
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Patient Sample 
Date 
Sex Age Growth Type and 
cfu/ml 
Antimicrobial therapy in 
previous 48h 
21 13/11/2006    Vancomycin, Meropenem, 
Fluconazole 
22 15/11/2006 M 65  Levofloxacin, Metronidazole, 
Benzylpenicillin 
23 27/02/2007 F 80 Klebsiella 
oxytoca^4 
Clarithromycin, Tazocin 
23 28/02/2007    Clarithromycin, Tazocin, 
Gentamicin 
23 02/03/2007   Klebsiella 
oxytoca^3 
Tazocin, Gentamicin 
24 27/02/2007 M 80 Pseudomonas 
aeruginosa^5, 
Staphylococcus 
sp.^3 and 
Baxteroides sp.^3 
 
24 28/02/2007   Pseudomonas 
aeruginosa^5 
 
25 27/02/2007 M 76 Klebsiella 
pneumonia^5, 
Enterococcus sp.^3 
Tazocin, Erythromycin 
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Patient Sample 
Date 
Sex Age Growth Type and 
cfu/ml 
Antimicrobial therapy in 
previous 48h 
26 27/02/2007 M 74  Meropenem, Clarithromycin 
26 28/02/2007    Meropenem 
26 02/03/2007    Amoxicillin 
27 05/03/2007 M 82 Pseudomonas 
aeruginosa^3, 
Candida sp.^5 
Imipenem, Clindamycin 
28 05/03/2007 F 78  Clarithromycin, Tazocin, 
Nystatin 
29 02/04/2007 M 58  Ceftriaxone 
30 08/05/2007 F 43  Meropenem, Vancomycin, 
Fluconazole 
31 25/06/2007 F 69  Tazocin, Rifampacin, 
Teicoplanin 
31 26/06/2007    Teicoplanin, Meropenem 
31 27/06/2008    Teicoplanin, Meropenem, 
Erythromycin 
32 26/06/2007 F 54 Candida sp.^5 Gentamicin, Meropenem, 
Fluconazole 
33 15/01/2008 M 62   
33 16/01/2008     
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Patient Sample 
Date 
Sex Age Growth Type and 
cfu/ml 
Antimicrobial therapy in 
previous 48h 
34 17/01/2008 F 82  Tazocin 
35 06/02/2008 M 65 Acinetobacter^5, 
MRSA^5 
Gentamicin, Benzylpenicillin, 
Clarithromycin 
35 08/02/2008   Acinetobacter^3, 
MRSA^3, 
Streptococcus sp.^4 
Benzylpenicillin, 
Clarithromycin, Linezolid 
36 27/02/2008 M 71 Candida sp.^4 Flucloxacillin, Rifampacin 
36 29/02/2008   Candida sp.^4 Flucloxacillin, Meropenem, 
Rifampacin 
37 29/02/2008 F 76  Meropenem, Tazocin 
37 03/03/2008    Meropenem, Tazocin, 
Teicoplanin 
37 07/03/2008    Erythromicin, Ciprofloxacin, 
Gentamicin 
37 10/03/2008    Erythromicin, Ciprofloxacin, 
Gentamicin 
37 12/03/2008    Ciprofloxacin 
37 14/03/2008    Ciprofloxacin 
37 17/03/2008   Staphylococcus 
sp.^3 
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Patient Sample 
Date 
Sex Age Growth Type and 
cfu/ml 
Antimicrobial therapy in 
previous 48h 
38 07/03/2008 M 77 MRSA^5  
39 14/03/2008 M 69 Enterobacter sp.^3 Ciprofloxacin 
40 02/04/2008 M 77  Ceftriaxone, Aciclovir 
41 07/04/2008 M 79 Candida albicans^3 Tazocin, Metronidazole 
41 09/04/2008   Candida albicans^3 Tazocin 
41 11/04/2008    Tazocin 
41 15/04/2008   Candida albicans^3 Meropenem 
42 08/04/2008 M 59   
43 10/04/2008 F 69 Staphylococcus 
sp.^3 
Gentamicin, Amoxicillin, 
Metronidazole 
44 16/04/2008 M 79 Candida sp.^3 Meropenem, Flucloxacillin 
Control1 12/03/2008 M 69  Ciprofloxacin 
Control2 19/03/2008 F 35  Erythromycin, Meropenem, 
Fluconazole 
Control3 20/03/2008 M 19 Neisseria sp.(x2)^3 Cefuroxime, Metronidazole, 
Flucloxacillin 
Control4 19/05/2008 M 60  Ciprofloxacin 
Control5 11/06/2008 M 46  Co-Amoxiclav 
Control6 25/06/2008 M 61   
Table 5.2 Microbiological growth and antimicrobial therapy by individual BAL sample. 
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Organism Isolated Number of Isolates 
Gram Positive  
Staphylococcus aureus 
(all MRSA) 
5 
Coagulase negative Staphylococci 13 
Streptococcus species 6 
Enterococcus species 1 
Aerococcus species 1 
Gram negative  
Klebsiella species 6 
Enterobacter species 4 
Pseudomonas aeruginosa 4 
Proteus species 1 
Stenotrophomonas species 1 
Acinetobacter species 2 
Neisseria species 1 
Bacteroides thetaiotaomicron 1 
Fungi  
Candida species 20 
 
Table 5.3 Number of isolates of the species grown from the bronchoalveolar lavage 
samples, in order of pathogenic potential.  The total includes those found in mixed 
growth samples. 
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Patient Number Age Sex Reason for Ventilation 
1 57 M Community Acquired Pneumonia/Pulmonary Oedema 
2 45 M VF arrest 
3 76 M Post op for scrotal sepsis 
4 79 M Community Acquired Pneumonia 
5 65 M Community Acquired Pneumonia 
6 38 F Overdose 
7 72 F Septic Arthritis, Acute Respiratory Distress Syndrome 
8 41 M Pelvic Trauma 
9 36 M Aspiration Pneumonia, Fitting 
10 68 F Metabolic acidosis and Acute Renal Failure 
11 56 M Head Injury 
12 61 F Out of hospital cardiac arrest 
13 66 F Acute hepatitis, Acute Respiratory Distress Syndrome 
14 76 F Sepsis 
15 52 M Pneumonia 
16 60 F Biliary Sepsis, VF arrest 
17 67 M Post op  total colectomy 
18 42 M Biliary Sepsis 
19 84 F Pancreatitis, Pleural effusions 
20 76 F Not documented 
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21 39 M Community Acquired Pneumonia, Empyema 
22 65 M Out of hospital arrest 
23 80 F Community Acquired Pneumonia 
24 80 M Perforated DU, Fast Atrial Fibrillation 
25 76 M Post op total colectomy 
26 74 M Respiratory failure, sepsis 
27 82 M Necrotising fascitits 
28 78 F CVA, Pneumonia 
29 58 M Community Acquired Pneumonia, COPD 
30 43 F Pelvic sepsis 
31 69 F Community Acquired Pneumonia 
32 54 F Anastamotic leak, Cardiac arrest 
33 62 M Post Oral Surgery 
34 82 F Sepsis 
35 65 M COPD 
36 71 M Sepsis 
37 76 M Post colonic resection 
38 77 M Post Cardiac Bypass surgery 
39 69 M Acute Pancreatitis 
40 77 M Encephalitis 
41 79 M Post colonic surgery 
42 59 M CVA 
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43 69 F Post Total Hip Replacement 
44 79 M Sepsis post Total Knee Replacement 
Control 1 69 M Acute Pancreatitis 
Control 2 35 F Acute Pancreatitis 
Control 3 19 M Dental Abcess 
Control 4 60 M Post Oral surgery 
Control 5 46 M Post Maxillectomy 
Control 6 61 M Post Maxillectomy 
    
 
Table 5.4 Summary of study participant demographics and reasons for ventilation. 
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5.7.1 Analysis of clinical samples 
Following headspace analysis of the clinical samples, the Enose data was correlated with 
growth information from the hospital microbiology lab using PC fed LDA.  Of the 102 
clinical samples collected 88 were used for further analysis; 4 samples had no Enose data, 
and 10 samples all measured on the same day were excluded as outliers (Figure 5.4). 
 
Of the 88 samples used for further analysis, 5 had Gram +ve growth, 7 Gram –ve, 8 
Fungi, 46 No growth, 10 Mixed growth, 12 No growth &  no antibiotics. 
 
Figure 5.4 Demonstration of outlier data that was excluded from the dataset for 
subsequent analysis. 
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A rudimentary classification differentiating samples with and without microbiological 
growth would allow the clinician to introduce empirical antimicrobial therapy earlier than 
would otherwise be possible. Therefore the performance of a two group clinical model 
was evaluated. Of the 88 samples,30 showed microbiological growth & PC fed LDA 
classification model demonstrated a training performance of 68.2%, which is shown in 
Figure 5.5. The classification performance is shown in Table 5.5. 
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Figure 5.5 Histogram of linear discriminant scores shows misclassification of a 
significant number of Enose fingerprints from samples with no microbiological growth 
(green bars) and samples with microbiological growth (red bars). In particular, 
misclassified no growth samples are seen, to the left of zero, overlapping the samples 
with microbiological growth. 
LD Score 
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 Enose prediction 
Growth No Growth 
Microbiology Gold 
Standard 
Growth 24 6 
No Growth 22 36 
Table 5.5 Classification performance of the two group clinical model 
 
12 samples were collected from patients who had not received antimicrobial therapy 
within 48 hours of sampling.  9 of these samples were culture negative and 3 grew 
organisms.  Therefore a further two group PC fed LDA classification model was 
developed with patients with no growth samples on antibiotics removed from the 
analysis. A classification model of the Enose fingerprints of the 9 no growth samples, 
from patients not on antibiotics, and 30 samples with microbiological growth, which had 
a training performance of 89.7% correct prediction (Table 5.6 & Figure 5.6). Further, 
77% of samples were correctly classified by the leave one out cross validated model, 
sensitivity and specificity of 56-83%. (Table 5.7). The decrease in the performance on 
cross validation indicates insufficient numbers of samples & patients are included in the 
model. 
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 Enose prediction 
Growth No Growth 
Microbiology Gold 
Standard 
Growth 28 2 
No Growth 2 7 
 
Table 5.6 Classification performance of the two group clinical model of the 9 no growth 
samples, from patients not on antibiotics, and 30 samples with microbiological growth. 
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Figure 5.6. Histogram of linear discriminant scores shows clear discrimination of the 
Enose fingerprint from samples without microbiological growth from patients not on 
antibiotics (green bars) and with microbiological growth (red bars). 
125 
 
 
 
 
 Enose prediction 
Growth No Growth 
Microbiology Gold 
Standard 
Growth 25 5 
No Growth 6 6 
 
Table 5.7 Classification performance of the leave one sample out cross validated two 
group clinical model of the 9 no growth samples, from patients not on antibiotics, and 30 
samples with microbiological growth. 
 
 
A clinically significant 4 group classification (Gram-positive, Gram-negative, Fungi and 
no growth) was then developed, to evaluate the Enose fingerprints from 29 samples; 9 
with no microbiological growth from patients not on antibiotics, 5 samples with Gram-
positive growth, 7 samples with Gram-negative growth and 8 with fungal growth.  
Samples with mixed growth were again excluded from this analysis.  Seventy six percent 
of samples were correctly classified by the model, with sensitivity 60-100% and 
specificity of 81-100% (Table 5.8 & Figure 5.7). 
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 Enose prediction 
Gram +ve Gram –ve Fungi No Growth 
Microbiology 
Gold 
Standard 
Gram +ve 3 1 1 0 
Gram –ve 0 7 0 0 
Fungi 0 3 5 0 
No Growth 0 1 1 7 
 
Table 5.8 Classification performance of a four group classification model developed with 
29 samples; 9 with no microbiological growth from patients not on antibiotics, 5 samples 
with Gram-positive growth, 7 samples with Gram-negative growth and 8 with fungal 
growth. 
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Figure 5.7 Scatter plot of linear discriminant scores of the electronic nose response to 
significant groups, Gram positive (◄), Gram negative (►), Fungi (●) and no 
microbiological growth (■).  
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The results of our Enose analysis of the BAL samples gave a significantly lower 
discrimination ability compared to what we had expected from other published work.  We 
postulated that this was due to patient related factors and the use of antimicrobial therapry 
prior to sampling.  In order to investigate this theory we constructed a “lab based model” 
using organisms isolated from the BAL samples and then grown on a culture medium.  
This allowed us to use exactly the same organisms but without the presence of the BAL 
fluid which we theorised contained elements of the host response to infection.  It also 
negated the problem of prior antimicrobial therapy. 
 
We accept that this is an artificial situation without direct clinical relevance, however it 
does allow us to demonstrate improved discrimination of the microorganisms seen. It has 
also provided the opportunity for discussion regarding the use of antimicrobial therapy 
and which host factors may be involved. 
For clarification of the following results, the first section (5.7.1) relates to the clinical 
BAL samples and the second section (5.7.2) relates to the “lab based model” described 
above. 
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5.7.2 The lab based model 
This section refers to the microorganisms isolated from the BAL samples and then grown 
in a culture broth before analysis.  The broth was used as a control. 
 
The measured Enose data was used in the development of multivariate classification 
models. PCA fed LDA showed discrimination of growth samples (bacterial & fungi) 
from the controls (Figure 5.8).  
 
Fig 5.8 PCA model demonstrating separation of the 12 microbial species and broth 
control samples on the basis of Enose data. From Sahgal, N 2008 [154] 
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Figure 5.9 Scatter plot of linear discriminant scores of the electronic nose response to 
microorganisms isolated from clinical bronchoalveolar lavage samples. Each 
measurement is coded according to the microbiological classification into four clinically 
significant groups, Gram positive (green), Gram negative (blue), Fungi (red) and controls 
(cyan).  These are the same species as shown in Figure 5.8 but grouped as described 
above. 
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The performance of the classification model was tested with leave one out cross 
validation demonstrated correct classification of 70% of samples with sensitivity 56-84% 
and specificity 81-97%. The classification breakdown is shown in Table 5.9 & Figure 
5.9. The decrease in the performance on cross validation indicates insufficient numbers of 
samples & patients are included in the model. 
 
 
 
 
Enose prediction 
Gram +ve Gram –ve Fungi No Growth 
Microbiology 
Gold 
Standard 
Gram +ve 19 2 9 4 
Gram –ve 6 24 0 0 
Fungi 4 0 10 1 
No Growth 2 0 1 16 
 
Table 5.9 Classification performance of a four group classification model with a leave 
one out cross validation of the electronic nose response to microorganisms isolated from 
clinical bronchoalveolar lavage samples. 
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Figure 5.10 Scatter plot of cross validated LDA classification model of the electronic 
nose response to microorganisms isolated from clinical bronchoalveolar lavage samples. 
Each measurement is coded according to the microbiological classification into four 
clinically significant groups, Gram positive (green), Gram negative (blue), Fungi (red) 
and no microbiological growth (cyan). 
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5.8 Discussion 
 
Thepurpose of this study was to assess the potential of the Enose in the clinical setting, 
therefore we looked at a clinically relevant four group model of Gram-positive, Gram-
negative, Fungi and no growth.  Whilst not as useful as knowing the exact organism 
present in the fluid, being able to identify which of these groups the infectious organism 
belongs to is clinically relevant and would allow the institution of narrower spectrum 
empiric antibiotic therapy whilst awaiting traditional culture results.  This would 
potentially mean reduced antimicrobial resistance and side effects, which are major 
problems as has already been discussed. 
 
This approach resulted in 83% classification accuracy when PCA fed LD analysis was 
used.  Not all the microbes grew well in the culture medium. In particular this was an 
issue for some Gram-positive organisms and the Candida species, which may be a reason 
why these samples group tightly to the uninoculated broth controls.  A different culture 
medium may suit these groups better, however it may be difficult to find a culture 
medium which provides optimal growth for all the different microbial species 
encountered. 
 
Dutta et al.[153] investigated the possibility of separating six species of bacteria 
responsible for eye infections in saline.  This was done using lab cultures and a 
conducting polymer Enose in conjunction with a neural network.  The bacterial 
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organisms were investigated in different concentrations.  Discrimination was not possible 
between the three different concentrations of individual bacteria.  However it was 
possible to discriminate between the different bacterial species when they were analysed 
at the same concentration.  The authors were also able to distinguish between 2 closely 
related Staphylococcus species when analysing 4 bacteria known to cause ENT 
infections.  The clinical samples were cultured on agar media overnight prior to analysis.  
This infers that bacterial agar cultures produce more volatiles when compared to culture 
broth.  This has also been suggested by Casalinuovo et al. [155] for bacteria but not 
yeasts.  No mention is made of the use of controls in either of these studies.  This may 
have had an impact on the ability to discriminate between species.    
 
 Analysis of the clinical BAL samples was first performed on the most basic level of a 2 
group model (growth vs. no growth).  A basic model like this would at least alert the 
clinician to the possibility of needing to commence empirical antimicrobial therapy if the 
clinical status of the patient gave cause for concern.  The model was constructed again 
using PCA fed LDA classification.  88 samples were included in the model, 58 with no 
microbiological growth and 30 with growth. 68% of samples were correctly classified 
using the leave one out cross validated model, with sensitivity and specificity of 67-69%. 
 
The aim of this study was to assess the ability of the Enose to discriminate between 
microbial isolates from patients and actual BAL samples from patients with or at risk 
from VAP.  For the in vitro studies on the isolates, twelve bacterial and yeast species 
were analysed together.  Only the Enterobacteriaceae could be clearly distinguished form 
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the other samples.  There also appeared to be a small distinction between the 
Streptococcus, Staphylococcus and Candida species.  It was impossible to discriminate 
between all 12 individual species.  This may be in part due to the small number of 
samples from each species. 
 
We have been concerned by the fact that the vast majority of our clinical samples were 
taken from patients who had been receiving antibiotic therapy in the 48 hours prior to 
sample collection.  As previously discussed this can have a significant effect on bacterial 
culture results.  This may be causing a false negative effect i.e. the Enose may be 
correctly classifying samples into the “growth” group but cultures are failing due to the 
use of antibiotics.  This could explain the reduced accuracy of the Enose on the clinical 
BAL samples when compared to the lab isolate samples. 
 
It is also unclear as to the basis on which Enose discrimination is taking place.  It may be 
that the Enose is capable of detecting the volatile fingerprint of microorganisms detected 
in the BAL fluid but his hypothesis is likely to be too simplistic.  The host response to 
infection is a complex and dynamic series of events that is under increasing investigation 
as a major contribution to death from sepsis.  The initial reaction relies on cellular and 
molecular components of the innate immune system.  Cytokines with proinflammatory 
roles such as tumour necrosis factor α (TNFα) are released along with components of the 
complement cascade.  The inability to regulate this inflammatory response in the 
presence of severe sepsis is characterised by widespread microvascular injury and 
thrombosis as well as multi organ dysfunction. 
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Bergeron et al.[156]studied the correlation between cytokine levels in lung tissue, BAL 
fluid and serum in relation to the time course and outcome of Streptococcus pneumoniae 
pneumonia in mice.  Samples were taken at time zero (pre-infection) and at 1, 2, 4, 12, 
24, 48, 72 and 96 hours post-infection.  They reported that TNFα was the first cytokine 
recovered from BAL fluid.  Levels showed a significant increase from 1-12 hours post 
infection when compared with pre-infection levels.  Levels rapidly dropped to normal 
after 12 hours indicating the TNFα rise in BAL fluid to be transient despite progression 
of the pneumonia.  TNFα levels in the lung tissue itself rose to very high levels at 12 
hours; this may indicate the involvement of interstitial inflammatory cells.  TNFα levels 
in serum were absent or at a very low level until 48 and 72 hours; at this time a very 
marked and rapid increase was noted.  This coincided with migration of bacteria to the 
bloodstream. The authors state that these findings clearly demonstrate 
compartmentalization of TNFα secretion to the site of infection, with successive 
appearances in BAL, lung tissue and finally blood. 
 
Interleukin-1 (IL-1) release was seen in lung tissue throughout the timecourse of the 
experiment combined with a very transient appearance of this cytokine in BAL and 
serum at 12 hours.  Both TNFα and IL-1 levels peaked at 12 hours in BAL and lungs.  
This is prior to bacterial dissemination to blood and may implicate these cytokines in the 
breaching of the alveolar-capillary barrier. 
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Interleukin-6 (IL-6) levels were significantly increased very early in BAL fluid and lung 
tissue after infection (2 hours), with a peak at 4 hours that also corresponded with partial 
release of IL-6 in serum.  Levels remained elevated throughout the experiment.  IL-6 
serum levels showed 2 time points for elevation; early at 4 hours and then later at 48 
hours until death.  This late rise correlated with bacteraemia. 
 
Leukotriene B4 (LTB4) levels, which were higher in BAL fluid than in the lung, increased 
in BAL fluid from 12-72 hours and in lung tissue at 24 hours, which accompanied and 
followed polymorphoneuclear cell (PMN) recruitment.  The amount of LTB4 recovered 
decreased with time, as did the number of monocytes and other secretory inflammatory 
cells in whole blood. 
 
Nitric oxide (NO) release was seen in the serum of infected mice throughout the 
experiment.  In contrast to this, a brief spontaneous release of NO was observed in BAL 
fluid 1 hour after infection, at a time when only alveolar macrophages are recovered from 
BAL fluid.  A second sustained phase (48-72 hours) of high NO secretion in lung tissue 
corresponded with the massive monocyte/macrophage recruitment period.  Tissue injuries 
attributable to high NO levels were seen during the same period. 
 
The presepticaemic and septicaemic stages of infection described in this study were 
demonstrated by the successive localisation of TNFα secretion to BAL fluid and blood 
respectively.  In the context of pneumococcal pneumonia, TNFα measurement could 
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prove useful for monitoring the presepticaemic and septicaemic stages of pneumonia.  
Monitoring of inflammatory mediators in BAL fluid could also generate markers of 
disease evolution, including cytokines, LTB4 and NO.  Whilst IL-6 in BAL fluid may be 
a good indicator of early infection, it did not reflect the evolution of infection and 
therefore cannot be measured in BAL fluid as a way of charting disease progression.  
TNFα secretion, in contrast to this, correlated with the initial inflammatory response 
localised to the lungs in the absence of systemic involvement.  There seems to be a 
spillover of IL-1 production from cells to fluids when overproduction occurs.  Detectable 
levels of IL-1 in serum or BAL fluid may therefore indicate a very active inflammatory 
response.  A combination of the profiles of TNFα in blood and NO in BAL provided an 
accurate estimation of disease state which chronologically correlated to a worsening of 
the pathological scoring of lung tissue. 
 
This paper demonstrates that a multitude of factors involved in the host response to 
infection can be observed in BAL fluid.  It is possible that these mediators of the 
inflammatory response may be contributing to the volatile fingerprints of BAL fluid from 
those patients with VAP.  Further work needs to be done to determine whether the Enose 
is capable of detecting the presence of these inflammatory mediators in BAL fluid.  It 
would also be interesting to see how the volatile fingerprint changes with time reflecting 
the changes in levels of individual compounds reported in the study by Bergeron et al. 
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5.9 Conclusions 
This study has demonstrated that the Enose is capable of accurately discriminating 
between samples in the lab based model.  The accuracy of this discrimination decreases 
when the clinical samples are analysed.  The reasons for this are unclear but there are 
several factors that are likely to be of importance.  The first of these is the use of 
antimicrobial drugs prior to sampling taking place.  These drugs are likely to be 
responsible for the reduced classification accuracy in the clinical sample model.  
Individual host response may also be playing a role.  We have discussed the fact that 
multiple inflammatory mediators are present in BAL fluid from mouse studies.  How the 
presence of these mediators affects the ability of the Enose to discriminate between 
samples is unknown. 
 
This method of BAL analysis using an Enose has shown promise as a near patient 
diagnostic tool but further work needs to be done.   In particular it would be interesting to 
repeat the study in a centre where the use of surveillance BAL sampling is standard.  This 
practice involves BAL samples being taken routinely from all ventilated patients on the 
first day of ventilation and subsequent days.  This design would yield large numbers of 
BAL samples from patients who are not on antibiotics and do not have VAP.  This would 
increase our number of no growth, no antibiotic samples.  Multiple samples like this 
would also allow us to develop a “BAL timeline” from individual patients who do not 
have VAP but subsequently develop it.  This would allow us to investigate changes in 
BAL fluid through the time course of the disease.  Further studies should be performed to 
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investigate the constituents of the inflammatory host response that may be detected in 
BAL fluid and how these affect Enose analysis. 
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Chapter 6 
GC-MS Analysis of Breath
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Modern breath analysis began in the 1970s when Pauling et al.[3] determined in excess of 
200 compounds in human breath using gas chromatography.  Gas Chromatography-Mass 
Spectrometry (GC-MS) has been widely used in the field of breath analysis ever since.  In 
this chapter we will focus on GC-MS analysis of breath samples collected from the same 
patients described in the previous chapter. 
 
6.1 Materials and Methods 
Breath samples were collected from patients immediately prior to them undergoing BAL 
sampling as described earlier.  Breath was collected using the “Breathotron” which was 
designed and built at Cranfield University.  A detailed description of the Breathotron can 
be found in the next chapter.  The ethical approval and consent process is the same as 
described previously. 
 
The Breathotron was connected into the closed circuit between the patient and the 
mechanical ventilator.  The sampling arm was connected as close as possible to the 
patient in the circuit to limit the number of VOCs detected from the various materials 
used to manufacture the breathing circuit and endotracheal tubes.  A Heat and Moisture 
Exchange bacterial filter was connected between the patient and the sampling apparatus.  
This was to prevent sputum and other potentially hazardous material contaminating the 
Breathotron.  This filter is designed to trap bacteria and does not impede the flow of 
VOCs from the expired breath into the sampling apparatus.   
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Breath is passed through standard stainless-steel automated thermal desorption (ATD) 
cartridges, containing dual packing comprising 50% Tenax TA and 50% Carbotrap 
(Markes International Limited, Llantrisant, UK).  These materials trap the compounds of 
interest for later analysis in the laboratory.  The Breathotron samples a small amount of 
air from each expired breath until a total volume of 500ml of expired breath has been 
passed through the sorbent trap.  This trap acts as a pre-concentrator of the VOCs prior to 
GC-MS analysis.  They also provide a stable transport and storage medium for the VOCs.  
The software on the Breathotron is set to sample the alveolar component of expired 
breath.  The sorbent traps were then sent to Cranfield University for analysis. 
 
ATD cartridges were conditioned before use by purging with helium carrier gas for 2 min 
at room temperature followed by 30 min at 335 ºC. Conditioned cartridges were then 
analysed by GC-MS using the protocol described below in order to confirm the 
effectiveness of the conditioning procedure. Conditioned cartridges were sealed with 
locking caps until required for use, a clean cartridge being used for each procedure. 
 
Captured volatiles were analysed using an AutoSystem XL gas chromatograph equipped 
with an ATD 400 thermal desorption system and TurboMass mass spectrometer (Perkin 
Elmer, Wellesley, MA). The heated valve of the ATD 400 was maintained at a constant 
180 ºC. CP grade helium (BOC gases, Guildford, UK) was used as the carrier gas 
throughout, after passing though a combined trap for the removal of hydrocarbons, 
oxygen and water vapour. The trap was renewed regularly following the manufacturer‟s 
recommendations. 
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Cartridges were desorbed by purging for 2 min at ambient temperature then for 5 min at 
300 ºC. Volatiles purged from the cartridge were captured on a cold trap which was 
initially maintained at 30 ºC. Once desorption of the cartridge was complete, the trap was 
heated to 320 ºC using the fastest available heating rate and maintained at that 
temperature for 5 minutes whilst the effluent was transferred to the gas chromatograph 
via a heated (210 ºC) transfer line coupled directly to the chromatographic column. 
 
A Zebron ZB624 chromatographic column was used (Phenomenex, Torrance, CA). This 
is a wall-coated open tubular column (dimensions 60m×0.4mm×0.25mm ID), the liquid 
phase comprising a 0.25 μm layer of 6% cyanopropylphenyl and 94% 
methylpolysiloxane. The gas chromatograph oven was maintained at 50 ºC for 4 min 
following injection and was then raised at 10 ºC.min-1 to 220 ºC for 9 min. Separated 
products were transferred by heated line, maintained at 240 ºC, to the mass spectrometer 
and ionised by electron bombardment. The spectrometer was set to carry out a full scan 
from mass/charge ratios (m/z) 33 to 350 using a scan time of 0.3s with a 0.1s scan delay. 
The resulting mass spectra were combined to form a total ion chromatogram (TIC) by the 
GC-MS integral software (TuboMass ver 4.1). 
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6.2 The structure of the GC-MS data 
The format of the GC-MS data is as follows: It is essentially a 3 dimensional array, where 
the data are individual time segments (typically 100 per second) of ion spectra and 
individual ion intensities. As compounds pass through the GC column, they are separated 
according to their physico-chemical properties, so small compounds, for example, pass 
through the column faster than large compounds and hence come off earlier. When they 
leave the column, they pass into the mass detector which bombards the compound with 
electrons, fragmenting them. The fragmentation pattern is characteristic of the compound 
and detector and can be used to identify it. 
  
Fig 6.1 Format of GC-MS data 
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The figure above shows how the data are formatted.  The top of 4 panels shows a total 
ion chromatogram. This shows the total ion count as detected by the mass detector as the 
compounds leave the gas chromatography column and is fragmented. A typical 
chromatography run will last for 30 minutes and resolve up to several hundred 
compounds. The detector produces a spectrum (3rd panel down) every 0.001 second (this 
is set by the user) of m/z value (essentially, this is the ion fragment mass) against 
intensity.  GC-MS data can be examined by other programs, and in conjunction with 
commercially available libraries, unknown compounds may be identified by comparing 
fragmentation patterns obtained with those in the library.  An example of such a program 
(used in this study) is AMDIS, Automated Mass Spectral Deconvolution and 
Identification System, developed by NIST, the National Institute of Standards and 
Technology. 
 
AMDIS uses the commercially available NIST library.  It works by matching a spectrum 
obtained at a particular scan number and finds the best match between that and spectral 
database entries in the library.  The difficulty is that in many cases, the library match does 
not give the correct compound, either because of noise, column bleed, or the co-elution of 
more than one compound, so it is often necessary to manually go through each resolved 
compound in the spectrum. This is very time consuming where there are a large number 
of data sets to look at. The AMDIS data can be imported into an Excel file and used to 
check compounds. Information about the retention time of known compounds also aids 
identification.  
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Analysis of GC-MS data ideally will enable unique biomarkers to be found for a 
particular disease. An example: suppose there are samples from people who have one 
disease, samples from people who have another disease and samples from people who 
have neither disease, i.e. there are 3 categories and hence 3 sets of sample data.  The aim 
would then be to find compounds that occur uniquely in samples of one disease or the 
other disease group, but not the non-diseased group.  In practice, this will mean finding 
the retention, or scan time where these differences occurs to enable specialists identify 
the specific compounds.  
 
 
6.3 Results 
A total of 101 breath and 1 ambient air samples were collected over the study period.  3 
breath samples were lost due to sampling errors.  This left a total of 98 breath samples 
collected from 44 patients and 6 controls. 
 
60 samples were scrutinised and the compounds present discerned. Of these 60 samples, 
35 samples were from patients with microbiological growth (this represents this entire 
patient group), 12 samples from patients with no growth and 13 samples from healthy 
volunteers.  The healthy volunteers‟ breath samples were collected for another study run 
by Cranfield University.  As we have no healthy patients in our study these were used for 
comparison.  2 samples from the growth group were discarded due to problems during 
the GC run.  This left a total of 58 samples. 
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The remaining 51 samples from patients with no microbiological growth were not 
included due to financial constraints with the analysis.   
 
The figures below show chromatograms from a “no growth” sample and a “growth” 
sample. 
 
Fig 6.2 Chromatogram of sample G107 as an example of a “no growth” sample. 
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Fig 6.3  Chromatogram of sample G165 as an example of a “growth” sample. 
 
  
Using AMDIS and the NIST database a list of the most likely compounds relating to 
retention times was compiled for each of the breath samples analyse.  Each individual 
breath sample contained between 223 and 525 different peaks which needed to be 
identified. 
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Toluene D8 was used as an internal standard in the analysis of each breath sample.  Fifty 
nanograms of Toluene D8 was introduced into the ATD tube prior to analysis.  By 
knowing the percentage of Toluene D8 detected by GC-MS analysis that equates to 50ng 
it is possible to approximate the amount in nanograms of the other compounds detected.  
This is an approximation only but is a valid calculation when comparing similar samples. 
 
Using this method the 30 most abundant compounds in each sample were identified and 
quantified.  These 30 compounds from each sample were then combined to make a list of 
253 different compounds that appeared in the 30 most abundant compounds across all the 
samples.  Anaesthetic gases were excluded from the top 30 list.  The amount in 
nanograms in compounds appearing in each sample was combined to allow PCA analysis 
in an attempt to differentiate between the healthy volunteers, growth and no growth 
groups. This table is too large to be displayed in the text but is included on the CD ROM 
(Table 6.1). 
 
Initially, 10 of the breath samples that were collected from patients who had 
microbiological growth at the time of collection and 10 samples from patients without 
microbiological growth were analysed.  By comparing the samples we found that the 
following compounds were present in the breath of all patients with microbiological 
growth but not present at all in the breath of those without microbiological growth.   
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These compounds were: 
Ethanol 2-phenoxy 
Ethyl Alcohol 
Furan tetrahydrochloride 
Heptane 
Hexane 
Isopropyl alcohol 
Propene 
 
To investigate whether any of these compounds represented potential breath markers for 
VAP, the remaining samples from patients with microbiological growth were analysed. 
From these results it was clear that there was no subset of compounds that were present in 
all the growth samples exclusively.  The following compounds were however present in 
the majority of the samples from patients with microbiological growth: 
Methyl alcohol  Acetic acid  Cyclohexane 
Nonanal   Acetaldehyde  Cyclohexanone 
Pentane   Acetone  Ethyl alcohol 
1,3 Butadene 2 methyl Acetonitrile  Heptane 
Toluene   Acetophenone  Isopropyl alcohol 
p-xylene   Benzaldehyde  Heptane 
Phenol    Benzene 
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Unfortunately as none of these compounds are present exclusively in the microbiological 
growth samples, none of these compounds can individually be considered breath markers 
of VAP merely by their presence or absence in a breath sample. 
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Fig 6.4 LD score plot showing all samples.  
 
Samples 26, 33-35 and 50 seen to be clear outliers on PCA (v high level of counts) 
therefore excluded from analysis 
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Figure 6.5 LD score plot showing differentiation of samples from healthy individuals 
(green), no growth BAL (blue) & growth (red). 
 
   
PCA fed LDA was performed on the samples which were split into 3 groups: 
1. Healthy Volunteers 
2. No growth 
3. Growth  
The results are displayed in figure 6.5 above. 
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Training Classification Performance  
Class 1  Percentage Correct 92.3077  
Class 2  Percentage Correct 90.9091  
Class 3  Percentage Correct 57.6923 
 
answer = 
 
    12     1     0 
     1    10     0 
     6     5    15 
Training performance 74.0000  
Prediction performance  0.0000  
 
LEAVE ONE OUT CROSS VALIDATION: 
answer = 
 
     9     0     4 
     0     8     3 
     0     1    25 
groupcorr = 
   69.2308   72.7273   96.1538 
Performance 84.0000 CORRECT 
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missed = 
 
     2 
    11 
    12 
    13 
    22 
    23 
    24 
 
The above are the samples misclassified by the model.  
 
Sensitivity 69-96%  
Specificity 71-100% 
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 A review of the PC loads was undertaken in order to ascertain which compounds were 
contributing most to the differentiation between groups.  This was done by marking the 
peaks in the loads.  This is illustrated in figure 6.6 below. 
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Figure 6.6 PC loads 1 to 10. 
Use ANOVA to identify significant PCs 
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Figure 6.7 PC 1 with significant peaks marked. 
13 - 1,3-Butadiene, 2-methyl- (isoprene) 
42 - 2-Propanol, 1,1,1,3,3,3-hexafluoro- 
76 -Acetaldehyde 
126 - Ethane, pentafluoro- 
 
Mean values of Isoprene in ng (Peak #13) 
Healthy volunteers 0 
No growth  469.76 
Growth  1508.28 
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Mean values of Acetone in ng (Peak #76) 
Healthy volunteers 264.10 
No growth  927.63 
Growth  3318.34 
 
Mean values of Acetaldehyde in ng (Peak #76) 
Healthy volunteers 9.6 
No growth  53.6 
Growth  122.4 
 
Mean values of Ethane,pentafluro- in ng (Peak #126) 
Healthy volunteers 0.86 
No growth  8.24 
Growth  98.25 
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6.4 Discussion 
The majority components of human breath are nitrogen, oxygen, carbon dioxide, water 
and inert gases.  The remaining small fraction of human breath comprises trace 
components occurring in concentrations in the nmol/l – pmol/l (ppbv-pptv) range.  More 
than 500 of these compounds have been described.  These volatile substances may be 
formed in the body or may be ingested or inhaled from the environment.  Exogenous 
molecules, especially the halogenated organic compounds may be analysed for 
environmental or expositional issues to assess compound specific uptake into and 
elimination from the body[157].  In order to establish which compounds are exogenous or 
may represent pathological processes within the body, it is important to establish which 
substances are endogenous. 
 
These endogenous compounds include inorganic gases such as NO and CO; VOCs such 
as ethane, pentane, acetone, isoprene; and other normally non-volatile substances such as 
isoprostanes, peroxynitrite or cytokines that can be determined in breath condensate. 
 
Quantitative analysis of breath condensate is impeded by several factors.  There is no 
clear relationship between assumed alveolar or airway concentrations and substance 
concentration in the condensate [158]; in addition some of these compounds are of 
limited stability. 
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Volatile organic substances such as ethane, pentane, isoprene or acetone can provide 
information regarding different biochemical processes in the healthy and diseased human 
body.  Kinetics of VOCs can be approximated according to substance solubilities.  In 
addition, for most of the exhaled organic compounds there are no problems with stability.  
 
6.4.1 What constitutes normal breath? 
The makeup of alveolar breath is distinctly different from that of inspired air.  VOCs 
present in alveolar breath are either extracted from the inspired ambient air or added as a 
result of metabolic processes within the body.  Some of these processes have been 
understood for many years, the most obvious being that oxygen is extracted from inspired 
air and carbon dioxide is added to alveolar breath via the oxidative metabolism of 
glucose[159]. 
 
In 1971 Pauling et al, demonstrated that several hundred VOC‟s could be demonstrated in 
normal human breath [3].  This number has now increased to several thousand 
compounds detectable in low concentrations [113].  This large number of compounds and 
the wide variation between individuals is a problem for the investigator.  In order to 
determine which breath VOC‟s are “abnormal” and therefore may be associated with a 
pathological process or disease, it is necessary to understand what can be considered 
normal. 
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In 1999 Phillips et al.[160] examined the breath of 50 healthy volunteers.  All subjects 
were fasted from midnight and samples were collected between 07:00 and 12:00 midday.  
The group studied comprised 27 males and 23 females.  The number of VOCs detected in 
individual breath samples varied from 157 to 241 with a mean of 204.2.  3481 different 
VOCs were observed at least once and only 27 VOC‟s were observed in all subjects.  The 
27 VOC‟s observed in all 50 subjects are shown in table 6.2 overleaf 
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VOC Positive/Negative 
 Alveolar Gradient 
Isoprene Positive 
Benzene, (1-methylethenyl) Positive 
Napthalene Positive 
2,5-Cyclohexadiene-1,4-dione, 2,6-bis(1,1dimethylethyl) Positive 
Napthalene, 1-methyl- Positive 
Butane, 2-methyl- Positive 
Tetradecane Positive 
Pentodecane Positive 
Dodecane Positive 
Benzene Negative 
Benzene, 1-ethyl-2-methyl- Negative 
Benzene, ethyl Negative 
Benzene, methyl Negative 
Benzene, propyl Negative 
Cyclohexane, methyl Negative 
Decane Negative 
Heptane Negative 
Heptane, 2-methyl Negative 
Heptane, 3-methyl Negative 
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Hexane Negative 
Hexane, 3-methyl Negative 
Nonane Negative 
Pentane, 2,3,4-trimethyl Negative 
Pentane, 2-methyl Negative 
Pentane, 3-methyl Negative 
Propane, 2-methoxy-2-methyl- Negative 
Undecane Negative 
 
Table 6.2 27 VOC‟s found in the breath of all 50 healthy volunteers (most abundant 
first).  Adapted from Phillips et al. 1999[160]. 
 
Phillips et al. use the concept of alveolar gradient as a method for compensating for 
VOCs that may be entering the body from the ambient air.  The amount of VOC in the 
ambient air is subtracted from the amount of the same VOC present in breath.  This gives 
the “alveolar gradient”.  A positive gradient indicates the VOC is endogenous and a 
negative gradient indicates the VOC has come from the ambient air.  This is a recognised 
attempt to compensate for environmental VOCs; however it has problems.  VOC‟s may 
be detectable in the breath for days or weeks after ingestion depending on the individuals‟ 
environment and other factors such as age and health.  Subtracting VOCs detected in the 
ambient air at the time of sampling does not correct for this phenomenon.  It is 
impossible to accurately account for this as the pathways by which many of these 
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compounds arise in the breath are unknown.  It also requires that two samples are 
collected and analysed for each patient studied. 
 
The alveolar gradient concept does give an indication of the kinetics of the VOC 
concerned within the body; this is because it varies with the rate of production and the 
rate of clearance of the VOC.  The polarity of the gradient shows whether production or 
clearance is the predominant process. 
 
An alternative method to compensate for the ambient air is to provide the patient with 
VOC-free air to breathe prior to collection of the breath sample.  This is a logical 
approach but very difficult to achieve practically; almost all “pure” air contains VOC‟s in 
picomolar concentrations. In practice it would take days or weeks of breathing pure air in 
order to eliminate the exogenous compounds found in ambient air.  
 
The body pool of VOCs is populated form two sources: the lungs and extra pulmonary 
sources.  The latter is usually from metabolic pathways but food, drugs and absorption 
via the skin may also contribute.  The movement of VOCs through the body is illustrated 
in figure 6.8 below: 
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Fig 6.8 Pathways of VOCs through body compartments.  Phillips et al 1999.[160] 
VOCs in the inspired air and the capillaries rapidly equilibrate in the alveoli.  The 
predominant process is dependent on the phase of respiration.  Room air VOCs 
equilibrate with lung venous blood during the inspiratory phase, whilst lung arterial blood 
equilibrates with VOCs in alveolar breath during the expiratory phase. 
 
Our results have shown no Isoprene in the breath of the healthy volunteers group and an 
increasing mean amount in the no growth and growth groups.  These findings are 
interesting for several reasons.  Firstly, Isoprene is ubiquitous in human breath and 
therefore should be present in all the samples analysed.  Isoprene has been identified as a 
marker of oxidative damage as we have already discussed.  The fact that Isoprene levels 
are elevated in all our study patients when compared to healthy volunteers can be 
167 
 
 
considered an indicator of their physiological state.  All of our study subjects are in the 
ICU setting receiving mechanical ventilation, which is clearly an abnormal physiological 
state.  If the patients in whom we have identified microbiological growth can be 
considered “sicker” than those in whom we did not culture any organisms then further 
elevations in breath Isoprene levels could be considered evidence that these patients are 
more “physiologically stressed”.   
 
Foster et al.[102] have postulated that an increased breath Isoprene level is an indicator of 
free radical mediated damage to lung epithelium.  We would expect damage to lung 
epithelium in the setting of VAP, but the use of mechanical ventilation itself may also be 
a cause of lung injury in our patient group. 
 
Breath Acetone is a marker of ketosis which is raised in starvation or in people with 
diabetes mellitus.  Our patient group showed an elevated mean acetone level in the breath 
when compared to the healthy volunteers.  Mechanically ventilated patients cannot 
consume what can be considered a “normal diet”.  Our subjects would either be in a state 
of temporary starvation or being fed either by a nasogastric tube or intravenously.  This 
may explain the elevated acetone levels seen in the study group.  We did also see a higher 
mean acetone level in the growth group compared to the no growth group. 
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Acetaldehyde is formed via the metabolism of ethanol in the liver.  Most of the literature 
on the presence of acetaldehyde in breath relates to its relationship with ethanol.  As our 
patient group are not in a position to be consuming ethanol we must look for another 
source.  It has been reported that oropharyngeal flora can produce acetaldehyde 
locally[161].  The presence of an endotracheal tube and critical illness can dramatically 
alter normal body flora including that in the upper respiratory tract.  Gas from here 
should be excluded when sampling via an endotracheal tube however it is well known 
that microorganisms colonise these devices and these could be contributing to the 
elevated acetaldehyde levels seen.  Further work is needed to investigate whether 
pathogens deep in the lungs as would be seen in VAP could be a potential source of 
increased breath acetaldehyde levels. 
 
Ethane,pentafluro is a refrigerant gas that is also used in fire suppression systems, it does 
not damage the ozone layer.  Its presence in the breath of our study subjects must be 
regarded as an exogenous compound.  The source of this and the reason its levels are 
higher in the growth patients then the no growth patients is unclear. 
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6.4.2 Volatile Inhalational Anaesthetic Gases 
22 samples analysed had Isoflurane, Desflurane or Sevoflurane (or a combination 
thereof) present.  These 22 samples were from 17 patients.  This finding is interesting as 
all patients were sampled at least 72 hours after any anaesthetic gases would have been 
given.  Isoflurane is 93% excreted via the lungs[162].  The finding of detectable levels of 
these gases in the breath of patients several days after administration is unexpected. 
 
A summary of samples with volatile anaesthetic gases detected by GC-MS analysis is 
included on the accompanying CD-ROM (Table 6.2). 
 
This prompted a review of the casenotes of the patients concerned.    The following 
points need explanation: 
 
1. Some patients have more than one type of anaesthetic gas detected in the breath 
when only one agent was given. 
2. Some patients have a different agent detected to the one given. 
3. We were unable to find any evidence of some patients being given any 
anaesthetic agent at all prior to sampling. 
4. The presence of significant amounts of these agents in the breath of study patients 
may be masking the presence of smaller quantities of significant VOCs of 
interest. 
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It is difficult to explain these anomalies satisfactorily.  The presence of anaesthetic agents 
in the breath when no agent has been administered, points to contamination.  This could 
either be from the gases the patient is breathing in or from the Breathotron machine itself.  
The fact that the patients are breathing piped gases from a closed circuit on a mechanical 
ventilator makes this extremely unlikely as a source of contamination.  GC-MS analysis 
of the inhaled gas mix for every sampled patient would have to be performed to 
conclusively exclude this as a source. 
 
It is possible that the residual breath in the sampling loop of the Breathotron could have 
been contaminated by samples of other patients.  This is only likely if patients had been 
sampled in quick succession in a “back to back” fashion.  As can be seen from the table 
above, none of the samples in which anaesthetic gases were detected were taken from 
different patients on the same day.   
 
A third source of potential contamination is the anaesthetic apparatus itself.  Prior to 
surgery the patient is anaesthetised in the anaesthetic room adjacent to the operating 
theatre.  After the patient is asleep they are disconnected from the anaesthetic machine 
and moved into the operating theatre.  Here they are connected to a second anaesthetic 
machine.  In the anaesthetic room the volatile agent of choice is commonly Isoflurane.  
When moved into the operating theatre, the patient could be continued on Isoflurane or 
switched to Desflurane or Sevoflurane depending on the Anaesthetist in charge of the 
case. 
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Another factor is that the breathing circuit (the tubing connecting the patient to the 
anaesthetic machine) is changed daily and can therefore be used for multiple patients in 
the same day.  Within these patients different anaesthetic agents could be used.  The 
breathing circuit does contain a single use filter which protects patients from infection.  
This filter would not however exclude volatile anaesthetic gases.  The anaesthetic 
machines and breathing circuits are the most likely source of contamination with volatile 
anaesthetic gases. 
 
However, none of the scenarios described above explain the presence of volatile 
anaesthetic gases in the breath of patients which have not been anaesthetised prior to their 
ICU admission.  Another finding that is difficult to explain is that in the 2 patients from 
whom we have more than one sample of breath containing anaesthetic gases, the amount 
of Isoflurane detected in the last sample is greater than that in the first sample.  Over time 
and without further exposure to Isoflurane the amount of Isoflurane detected in the breath 
should be decreasing. 
 
It is possible that the hospital notes are incomplete and anaesthetic charts or operation 
notes have been lost or misfiled.  However, the amounts of anaesthetic gases detected in 
the breath of the patients who do not appear to have been given any volatile anaesthetic 
gases are very small indeed.  This suggests contamination of the sample.  
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A literature research reveals no studies that have looked at the amounts of volatile 
anaesthetic gases in exhaled breath over time using GC-MS in critically ill patients.  
Carpenter et al.[162] looked at the metabolism of anaesthetic gases in healthy patients.  
They used GC-MS analysis of breath samples over a period of up to nine days in an 
attempt to quantify how much of these agents are excreted unchanged in breath and how 
much is altered by metabolism prior to elimination.  They measured the total amount of 
Isoflurane (and also enflurane, halothane and methoxyflurane) taken up during a 2 hour 
“wash in” period and then the total amount recovered unchanged in exhaled breath over a 
5-9 day “washout” period.  Using this method they concluded that 93% of the total 
amount of inhaled Isoflurane is excreted unchanged in breath over the washout period.  A 
total of nine patients were studied.  It should be noted that all nine patients received a 
mixture of all four anaesthetic agents in conjunction with nitrous oxide for 2 hours.  The 
study describes the total amounts of gases recovered in the breath, but the individual 
amounts detected at each of the sampling times throughout the washout period are not 
reported.  This does not give a picture of breath excretion over time, merely the total 
amount recovered. 
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These findings are very different to details quoted in the product data sheet (Rhodia, New 
Zealand. 1999): 
 
“In man about 0.2% administered is evident as recoverable 
metabolites (fluoride and organic fluorine), with approximately 50% of these 
excreted in the urine, the principal metabolite being trifluoracetic acid. 
Enzyme induction associated with pre-existing drug therapy would not appear to 
be an important factor in the metabolism of ISOFLURANE in man, mainly because 
the overall metabolism of ISOFLURANE is so low” 
 
Further work is necessary to establish over what time period volatile anaesthetic agents 
can be detected in the exhaled breath of critically ill mechanically ventilated patients.  
The effects of altered vital organ function and multiple drug interactions in this patient 
group may well have a significant impact.  It would also be interesting to measure levels 
of these compounds in the ambient air of the ICU environment as this could have 
implications for ICU staff with chronic, low level exposure to these compounds.  
Summer et al.[163] published a study looking at Sevoflurane concentrations in expired 
breath of operating room staff, using Proton Transfer Reaction Mass Spectrometry.  They 
sampled the breath of 40 staff members before commencing duty and at 0, 1, 2 and 3 
hours after finishing duty and again before commencing duty the next day.  Sevoflurane 
levels in exhaled breath of OR staff was significantly elevated at all time compared to 
control subjects who did not work in the OR. 
174 
 
 
 
The level of exposure in the ICU should however be far less as except on rare occasions 
patients do not receive volatile anaesthetic gases in the ICU. 
 
The results could also have implications for any further work on VAP and exhaled breath 
as the high levels of these compounds detected by GC-MS in the initial few days after 
anaesthesia could mask compounds of interest that may be present at much lower 
concentrations. 
 
It may be that such a study is unlikely to yield meaningful results as the ICU patient 
population is a heterogenous group with multiple pathologies and varying degrees of 
organ dysfunction as well as a wide variation of drug therapies.  
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Chapter 7 
The Breathotron
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7.1 Background 
The Breathotron is an evolution of the eNostril developed by Lee-Davey at Cranfield 
University in 2004[164].  The Breathotron is a novel breath analyser conceived and built 
by Cranfield Health.  It was initially intended for use in chronic health conditions such as 
cystic fibrosis and diabetes.  The Breathotron contains a single Mixed Metal Oxide 
Sensor as opposed to the traditional multiple sensor arrays employed in most electronic 
noses.  The sensor of choice is the CAP25, manufactured by Capteur (City Technology 
Ltd, Portsmouth, England).  A single sensor has been used in an attempt to increase 
portability and affordability when compared to commercially available Enoses. 
 
The CAP25 is a general air quality sensor, originally intended for automotive and 
aerospace applications.  It was selected due to its broad band response and low cost.  The 
Breathotron is a stand alone, mains powered portable device which can be controlled 
either by the built in portable digital assistant (PDA) or by connection to a PC.  The PDA 
is controlled by eNostril software which was written in house at Cranfield Health.  
Operating instructions can be found in Appendix 2.  A photograph of the Breathotron and 
a schematic are shown below. 
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Fig 7.1  The Breathotron. 
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Fig 7.2 Breathotron Schematic. 
 
The Breathotron also incorporates a sorbent trap to allow the collection of breath samples 
for GC-MS analysis as described in the previous chapter.  It therefore has the potential to 
incorporate both Enose analysis and collection of alveolar breath samples for GC-MS 
analysis in one portable unit.  In this study the Mk IIa version of the Breathotron was 
used. 
 
The following is taken from the operating instructions in Appendix 2: 
 
The version of the eNostril software used in this study is designed to enable the 
Breathotron to sample alveolar breath. The signal from the flow rate sensor is integrated 
so that the cumulative exhaled volume for any given breath is known, and sampling is 
initiated when this exceeds the estimated volume of the upper respiratory tract and the 
dead space of the face mask assembly. 
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The sampler incorporates two distinct methods for measuring compounds contained in 
the breath. In the first method, breath is passed through a cartridge containing granules of 
special polymers and/or activated carbon which trap the compounds of interest for later 
analysis in the laboratory. The second method uses a semiconductor sensor (mixed metal 
oxide sensor, MMOS) which produces an electrical signal in response to a broad range of 
compounds typically found in breath. This signal is digitised and stored on the PDA for 
subsequent numerical analysis. After sampling, breath is vented to the atmosphere and no 
gaseous samples are retained. 
 
In order to present a defined sample to the MMOS sensor, the Breathotron incorporates a 
sampling loop of fixed known volume. To pass a sample across the sensor, the loop is 
first switched into the sampling position so that it becomes charged with air or breath 
drawn in via the sampling port. When fully charged the loop is switched into the flush 
position, in which its contents are driven across the sensor using cleaned air at a fixed 
flow rate. Appropriate pumping and switching arrangements are provided so that a 
constant flow rate (required for correct operation) is maintained across the sensor while 
the instrument is in operation. 
 
The Breathotron was originally intended to be used by awake, spontaneously breathing 
patients via a disposable facemask.  However, for the purposes of this study it was 
modified to allow connection into the breathing circuit of a mechanical ventilator 
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7.2 Data Analysis 
The raw data gathered from the MMOS sensor response profile is digital in nature.  To 
allow further analysis this information must be converted via an analogue digital 
converter (ADC) stage[165].  The resulting output data can then be subjected to 
processing using a variety of techniques such as principal components analysis (PCA), 
discriminant function analysis (DFA), cluster analysis or artificial neural network (ANN). 
 
Following feature extraction as described below, the MMOS sensor data was analysed 
using Matlab 7.2. 
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7.3 Feature Extraction 
The figure below shows a typical response curve from a mixed metal oxide sensor. 
  
Fig 7.3 Dynamic response of MMOS sensor. (Adapted from Gardner and Bartlett 
1999)[166] 
 
Feature extraction is a technique for reducing the number of variables needed to describe 
a large set of data effectively.  Utilising this technique means that the entire response 
curve is not necessary.  Key features such as maximum signal height, baseline and the 
area under the curve as well as a variety of others can be used to describe the data.  
Analysing large sets of variables is time consuming; feature extraction can be employed 
to determine the most accurate combination of variables that describe the data. 
183 
 
 
 
Four commonly extracted features are illustrated in the figure below.  (a) shows the 
difference between peak resistance and baseline, (b) shows the total area under the curve, 
(c) the area under the curve from start of the signal to maximum response and (d) is the 
time from beginning of the signal to maximum response.  
 
 
Figure 7.4 An example of feature extraction. Carmel et al. 2003[167] 
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7.4 Breath Sampling 
 
Fig 7.5. Respiratory Volumes and Capacities from Tamarkin[168] 
 
The figure above is a schematic representation of the constituents of lung volumes.  It is 
necessary to have a basic understanding of lung physiology and breathing in order to 
understand breath sampling. 
 
An average 70kg human at rest inhales and exhales around 500ml each breath, this is 
known as the tidal volume.  As can be seen from the above figure, the total lung capacity 
is about 6000ml.  The vital capacity is the maximum amount of air that can be inhaled 
with a deep breath and then exhaled, this is approximately 4800ml.  The remaining 
1200ml (residual volume) remains in the lung and bronchial tree.  Dead space gas is air 
within areas of the respiratory tract in which gas exchange does not take place and is 
about 150ml or 30% of tidal volume.  As has already been discussed in the previous 
chapter alveolar air and not dead space gas contains the VOC‟s which are of interest, so it 
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is important to avoid sampling dead space gas if possible.  As part of this study is to 
evaluate the Breathotron as a breath collection device, there follows a description of some 
other alveolar breath collection devices. 
 
7.4.1 Breath Collecting Apparatus (BCA) 
This was developed by Phillips in 1997 in order to facilitate the collection of alveolar 
breath for GC-MS analysis.  This is a research tool and not commercially available. 
Advantages of the device are: 
1. Minimal resistance during exhalation which enhances patient comfort. 
2. Sterile, single use mouthpieces prevent the risk of cross infection. 
3. Alveolar breath sampling avoids dead space gas. 
4. Collects breath onto a sorbent trap allowing preconcentration. 
 
Operation 
The patient is fitted with a nose clip and breathes through the disposable mouthpiece into 
the device.  Breath is exhaled into a reservoir which is open to the room at one end.  As 
the patient exhales the residual air in the reservoir is forced out into the atmosphere.  The 
sampling port is as close to the subjects‟ mouth as possible, this means the deadspace gas 
exhaled will be at the furthest end of the reservoir.  This allows sampling of alveolar air.  
This method of collecting exhaled breath in a long, tubular reservoir; known as a 
Haldane-Priestly tube, is used commonly.  Reservoir tubing is heated to 40°C to prevent 
condensation of breath vapour on the internal surfaces of the device.  It takes 
approximately 5 minutes to collect the 10l of breath required for sampling. 
A schematic of the device is shown in the figure below. 
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Fig 7.6 Breath Collecting Apparatus from Phillips 1997[113] 
187 
 
 
 
7.4.2 Portable Spirometer/Alveolar Breath Collection system( Raymer et al 1990)[169] 
This is again an experimental tool and is not commercially available.  The device samples 
alveolar breath into evacuated stainless steel containers for GC-MS analysis.  Advantages 
of the device include its portability and its components can be easily sterilised and 
therefore reused. 
 
Operation 
The principle of operation is also based on the Haldane-Priestly tube.  The reservoir in 
this case is a Teflon tube with a capacity of one litre; samples are collected from the 
reservoir and stored in an evacuated stainless steel canister.  Volunteers inhale filtered 
VOC free air to prevent contamination from VOC‟s in the ambient air.  
The device is illustrated below: 
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Fig 7.7. Portable breath collection system (Raymer et al., 1990).  Numbered parts as 
follows: (1) organic vapour respirator cartridge; (2) flexible disposable polyethylene 
tubing; (3) one way Teflon inhale valve; (4) mouth piece; (5) one-way Teflon exhale 
valve; (6) Teflon tube to contain exhaled breath; (7) sampling port; (8) flow restricting 
orifice; (9) on-off valve; (10) polished canisters; (11) aluminium platform; (12) handle; 
(13) handle; (14) aluminium case. 
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7.4.3 End-Expiratory Air Sampling Device (Yeung et al., 1991)[170] 
This device was developed to monitor breath hydrogen concentrations in infants to aid in 
the clinical diagnosis of lactose malabsorption.  Breath is collected and stored in a 
syringe for GC-MS analysis.  This is again a research tool only. 
 
Operation 
Seven tungsten hot-wires are employed to measure the exhaled breath.  These form part 
of a Wheatstone bridge circuit which is cooled by breath.  The change in voltage can be 
translated into a flow rate.  The breath is sampled via a set of nasal prongs. A 1ml sample 
is required and this can be collected in 0.5-4 minutes.  The breath collected is stored in a 
glass syringe. 
A schematic of the device is shown below: 
190 
 
 
 
Fig 7.8 Schematic of End-Expiratory Air Sampling Device (Yeung et al., 1991) 
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7.4.4 Breath Sampler for Solvent Analysis (Dyne et al., 1997)[171] 
This device is commercially available as the “Bio-VOC” sampler from Markes 
International Ltd.  It is designed to collect alveolar breath samples and store them on a 
sorbent tube for GC-MS analysis. 
Advantages include: 
1. Alveolar breath sampling 
2. Easily portable 
3. Simple to use 
4. Designed to work with standard laboratory equipment 
 
Operation 
Again based on the Haldane-Priestly tube; one way valves trap the exhaled gas in the 
reservoir for collection.  An 85ml Tedlar bag is housed inside a rigid case and the device 
is attached to a sorbent tube.  The sample is forced into the sorbent tube by collapsing the 
Tedlar bag inside the case.  The device utilises disposable mouthpieces and an aluminium 
case. 
A cross section of the device is shown below: 
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Fig 7.9  Breath sampler in cross section (Dyne et al. 1997) 
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7.4.5 CO2 Alveolar Gas Sampler (Schubert et al., 2001)[111] 
This device was used to collect alveolar gas samples from mechanically ventilated 
patients.  The alveolar phase of expiration was detected by measuring exhaled CO2 levels.  
Sampled breath is stored on sorbent tubes for GC-MS analysis.  This is a device for 
research applications only.  It was designed to evaluate the use of expired CO2 
concentration as a trigger for alveolar breath sampling. 
Operation: 
A 930 Siemens-Elema CO2 analyser is used to detect the alveolar phase of respiration.  
The analyser works on the principle of infra red adsorption to detect CO2.  When the CO2 
concentration reaches 5-6% a valve is activated to direct the breath onto the sorbent traps.  
Medical grade plastics are used in the construction of this device as are glass and 
stainless steel components.  A schematic is shown below: 
 
Fig 7.10 Schematic of the CO2 Controlled Alveolar Sampler 
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7.4.6 Alveosampler (Quinitron) 
This is a commercially available, disposable device produced by Quinitron.  It allows 
collection of alveolar breath samples which are then stored in an ordinary syringe. 
 
Operation 
Again this device is based on the Haldane-Priestly tube, however this device employs a 
bag as the reservoir as opposed to a rigid tube.  The majority of the device is made from 
medical grade plastic but the bag material is not disclosed.  Mouthpieces are disposable 
and cardboard.  A picture of the device is shown below: 
 
Fig 7.11 The Quinitron Alveosampler (www.quinitron-usa.com) 
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7.5 Research Aims 
The aim of this study is to attempt to differentiate between the breath of patients who 
have microbiological growth on BAL samples and the breath of those with no 
microbiological growth.  We are attempting to identify those mechanically ventilated 
patients who have or who are at risk of developing VAP.  We are also evaluating the 
Breathotron as a means of sampling alveolar breath. 
 
7.6 Materials and Methods 
The same set of patients that have been described in the previous chapters are studied in 
this chapter.  A total of 102 samples were collected.  101 from patients and 1 ambient air 
sample.  2 data files were lost by the software and 6 data files were unusable due to 
problems with the sensor equilibrating.  This left a total of 94 samples from the MMOS 
sensor for analysis. 
 
Samples were taken at the same patient encounter as the BAL samples described earlier 
in this thesis.  The BAL sample was taken first and then the Breathotron was connected 
into the ventilator circuit, this was to eliminate any effect the normal saline lavage may 
have on the respiratory tract. 
 
The Breathotron was set up and allowed to equilibrate for 15 minutes prior to each 
sampling episode as detailed in the operating instructions appended.  Sample collection 
was performed according to the operating instructions.  The sensor response is stored on 
196 
 
 
the PDA as a text file.  The text files were then imported into Microsoft Excel to allow 
further analysis in Matlab 7.2. 
 
7.7 Results 
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Fig 7.12 Examples of traces from Breathotron MMOS sensor from multiple sampling 
episodes. 
 
Fig 7.12 above shows the features of the response curve from the Breathotron MMOS 
sensor.  Data 2 and 6 show typical examples of the response curve with the initial 
baseline, peak and then return to baseline.  The other traces are examples of bad samples 
where the sensor did not have enough time to equilibrate before sampling began. 
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Fig 7.13 below shows an example of how a best fit curve has to be constructed to 
compensate for the noisy data.  
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Fig 7.13 Best fit curve applied to MMOS sensor data. 
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7.8 Discussion 
The drive towards non-invasive near patient diagnostic techniques is growing in the 
medical community.  The Breathotron represents an attempt to combine two technologies 
currently in use for breath analysis.  The MMOS sensor analysis represents a true rapid, 
near patient diagnostic tool; whilst the collection of samples for GC-MS analysis allows 
for quantitative analysis of the compounds involved.  The use of a single sensor as 
opposed to a multi sensor array approach is attractive but one sensor may not have the 
ability to discriminate in the same way as a multi sensor array.  Following the GC-MS 
analysis it may be possible to change the single senor once the target compounds of 
choice have been identified, this approach may allow the use of a single sensor to be 
effective. 
 
The Breathotron mark IIa as used in this study is portable although not lightweight.  It 
does make a loud buzzing noise whilst in use.  This is not a significant problem for 
unconscious patients but can become wearing for the operator performing multiple back 
to back sampling.  After initial instruction and demonstration in its use, it was on the 
whole easy to operate.  The battery life of the PDA became a problem when the machine 
was not in use as the battery goes flat in about 5 days.  This causes loss of the enostril 
software, but not data as this is stored on the SD card as opposed to the internal memory.  
This is a minor annoyance but is a problem with PDA‟s in general and not the actual 
Breathotron itself.  The software is easy to reinstall once the PDA has been recharged. 
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The Breathotron is easy to connect into the ventilator breathing circuit with only a short 
disconnection time for the patient.  This caused no more patient discomfort than 
undergoing routine suctioning of secretions.  Towards the end of the study, the MOS 
sensor began to take longer to equilibrate than it had in the early stages.  This may be a 
result of sensor drift after repeated use.  It could also be a result of the high water content 
of breath.  This did not seem to affect results as long as sampling was delayed until the 
sensor appeared stable on the PDA display. 
 
Analysis of the raw data was performed according to the feature extraction techniques 
described by Jon Lee-Davey in 2004.[164]  The initial upstroke following the plateau 
phase of the curve represents the point at which the Breathotron switches the flow of the 
breath sample from the sorbent trap for GC-MS analysis to the MMOS sensor.  This point 
has to be manually marked on each sample curve via a Matlab 7.2 plug in.  This allows 
data to be normalised form this point.  The time at which the switching occurs is different 
because it is determined by the volume of breath sampled rather than a set time. 
 
PCA analysis of this data did not show any separation when compared with the growth or 
no growth BAL results.  This is most likely a reflection of the use of a single sensor as 
opposed to a sensor array.   Another issue is the choice of sensor employed in the 
Breathotron.  As already discussed this is designed for general air quality measurements 
and not for breath sampling.  The single sensor approach may be valid in this setting if 
more information on the VOC‟s of interest can be established through GC-MS or SIFT-
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MS analysis.  This may allow the choice of sensor used to be “tuned” to these VOC‟s 
allowing for more accurate discrimination. 
 
7.9 Conclusions 
The Breathotron represents an ambitious attempt to create a portable, near patient device 
for breath analysis combining two distinct methods of analysis.  Its usefulness as a 
collection device for breath samples onto sorbent traps to allow GC-MS analysis has been 
demonstrated.  The use of the single sensor approach as opposed to a sensor array has not 
yielded any useful results in this work.  Future generations of the Breathotron need to be 
lighter, quieter and have a modified single sensor.  It may be that a mini sensor array of 4 
or 5 sensors could be created which would retain the portability but improve accuracy. 
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Chapter 8 
Conclusions 
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The diagnosis of VAP remains a difficult and contentious issue.  We have investigated 
several novel techniques that could be employed in this area.  Of all these; the Enose 
analysis of BAL fluid looks to be the most promising.  The accuracy achieved in the lab 
based model is comparable to the microbiological techniques which are used currently in 
the diagnosis of VAP.  The accuracy did decrease when clinical samples were introduced 
and the possible reasons for this have been discussed in Chapter 5.  Further studies are 
needed with much larger sample numbers in order to gain a true picture of the role Enose 
technology has to play in this field.  In particular, the use of “surveillance BAL 
sampling” in patients not on antimicrobial therapy, would yield large numbers of BAL 
samples with no growth which should allow us to establish more clearly what non- 
colonised or infected samples “smell” like. 
 
The GC-MS analysis of breath samples did not yield any biomarkers as we had hoped.  
What did become clear is that the science of breath analysis is very complex with huge 
amounts of data generated from each individual sample.  Reducing this data and 
comparing it with a database of potential compounds requires large amounts of skill, 
experience and indeed time.  The wide variation of compounds found in the breath of 
normal healthy volunteers, let alone the critically ill patient is one of the most difficult 
aspects of this diagnostic approach to deal with.  Breath analysis is quite a way from 
becoming an accepted mainstream diagnostic technique for these reasons and also due to 
the lack of agreement amongst those that work in this field on how to standardise the data 
and how to deal with the problems of establishing which compounds are exogenous.  
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Despite these shortcomings, breath analysis still remains a tantalising and exciting area of 
research with the potential to detect disease painlessly and non-invasively.    
 
Finally, we evaluated the Breathotron with its single MMOS sensor.  As discussed the 
single sensor approach did not yield any useful results in this study.  However replacing 
the sensor with a different model which is more sensitive to the compounds we have 
found during the GC-MS analysis may help to improve the unit‟s performance.  It may 
also be that a sensor array will be necessary as no single sensor has the ability to 
distinguish the compounds of interest with any accuracy.  The Breathotron did prove an 
accurate and reliable method of breath collection for GC-MS analysis.  This could be 
improved if the unit could be made smaller, lighter and quiter.
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CV for Catherine Kendall   
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Provisional opinion 
 
The Committee would be content to give a favourable ethical opinion of the research, 
subject to receiving a complete response to the request for further information set out 
below. 
 
Authority to consider your response and to confirm the Committee‟s final opinion has 
been delegated to the Chair. 
 
Further information or clarification required 
 Please produce a simplified version of Patient Information Sheet for patients who 
later have to give retrospective consent.  Data from patients who do not give 
retrospective consent must be destroyed. 
 Assent Form 
o Second statement change to „I agree to samples from my relative being used 
in the research project as described in the information sheet.‟ 
o Add a space for the name of the patient and the relationship the patient has to 
the person who has given assent. 
 Application Form  
o A36, NHS indemnity does not cover non-negligent harm.  Normal trust 
complaints procedures apply and the trust may make an ex-gratia payment. 
o A51, the committee require more detail on the sample size calculation. 
o A53, the committee would like to know why you are using „Principal 
Component Analysis‟. 
 You need to investigate whether the filters on the ventilators remove the gases being 
studied. It is thought that only bacteria organisms are removed but clarification is 
needed. 
 Relative Information Sheet 
o It is not clear on the information sheet for relatives that should they not give 
assent then their relative will not be included in the study. 
o The applicant was asked to personalise the information sheet for relatives e.g. 
„Will my details be confidential’ should be changed to „Will my relative’s 
details be confidential?‟ This is suggestive, not exhaustive.  All elements need 
personalising. 
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 The tandem breath analysis should be carried out before the BAL.  This will exclude 
any potential confounding. 
 The management and security of electronic patient data is adequate.  However the 
application lacked detail on the storage of paper documentation e.g. consent forms.  It 
is not clear as to where, by whom and for how long these will be retained. 
 
When submitting your response to the Committee, please send revised documentation 
where appropriate underlining or otherwise highlighting the changes you have made and 
giving revised version numbers and dates.   
 
The Committee will confirm the final ethical opinion within a maximum of 60 days from 
the date of initial receipt of the application, excluding the time taken by you to respond 
fully to the above points.   A response should be submitted by no later than  02 March 
2006. 
 
Membership of the Committee 
 
The members of the Ethics Committee who were present at the meeting are listed on the 
attached sheet. 
 
Statement of compliance  
 
The Committee is constituted in accordance with the Governance Arrangements for 
Research Ethics Committees (July 2001) and complies fully with the Standard Operating 
Procedures for Research Ethics Committees in the UK.  
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Operating Instructions for the Cranfield University 
Tandem Breath Analyser 
(Breathotron Mk IIa) 
Version 0.0 
February 2006
 1 
Outline of operation 
The Breathotron is an instrument which samples expired human breath for chemical 
analysis. It is a prototype unit which was developed in the Department of Analytical 
Science and Informatics at Cranfield University. It is a stand-alone, mains-powered, 
portable unit, which is software controlled using the incorporated hand-held computer 
(personal digital assistant or PDA). 
To use the instrument, the volunteer wears a facemask and continues to breathe 
normally (i.e. no specialised manoeuvres need to be learned). Non-return valves in the 
mask ensure that the volunteer inhales ambient air and exhales though a wide-bore tube 
containing a flow rate sensor. The sensor is used to monitor the flow rate during 
exhalation and this is used to control the sampling process. A small proportion of each 
expired breath is drawn off via a narrow-bore sampling line and passed into the 
instrument. 
The current version of the eNostril software is designed to enable the Breathotron to 
sample alveolar breath. The signal from the flow rate sensor is integrated so that the 
cumulative exhaled volume for any given breath is known, and sampling is initiated 
when this exceeds the estimated volume of the upper respiratory tract and the dead 
space of the face mask assembly. 
The sampler incorporates two distinct methods for measuring compounds contained in 
the breath. In the first method, breath is passed through a cartridge containing granules 
of special polymers and/or activated carbon which trap the compounds of interest for 
later analysis in the laboratory. The second method uses a semiconductor sensor (mixed 
metal oxide sensor, MMOS) which produces an electrical signal in response to a broad 
range of compounds typically found in breath. This signal is digitised and stored on the 
 2 
PDA for subsequent numerical analysis. After sampling, breath is vented to the 
atmosphere and no gaseous samples are retained. 
In order to present a defined sample to the MMOS sensor, the Breathotron incorporates 
a sampling loop of fixed known volume. To pass a sample across the sensor, the loop is 
first switched into the sampling position so that it becomes charged with air or breath 
drawn in via the sampling port. When fully charged the loop is switched into the flush 
position, in which its contents are driven across the sensor using cleaned air at a fixed 
flow rate. Appropriate pumping and switching arrangements are provided so that a 
constant flow rate (required for correct operation) is maintained across the sensor while 
the instrument is in operation. 
Setting up 
Connections 
The instrument case houses the power supply, mains cable and USB lead for the PDA. 
The PDA itself, facemask, valve and sampling line are separate. Make the following 
connections: 
 3 
1. Lead from the power supply to the three-pin power connector at the centre rear 
of the top panel. 
2. The sampling line to the screw thread connector at the right rear of the top panel. 
The nut should be done up finger tight then secured with approximately ¼ 
clockwise turn using an 11mm spanner, to ensure an airtight seal. 
3. The lead from the flow rate sensor to the 4-pin socket adjacent to the sampling 
line connector. 
4. The USB connector to the socket in the base of the PDA. 
5. Mains connector to a convenient outlet. Note that the power supply can be 
detached from the lid of the case if greater reach is needed. 
Figure 1 shows the Breathotron and its connections. 
 
Figure 1 Breathotron Mk IIa. General view showing the instrument ready for use. 
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 4 
Startup 
On switching on (the on/off switch is the only hardware control) the blue power 
indicator will light and then, after a five-second pause, the sampling pumps will start to 
run. The Breathotron uses two pumps, for the sorbent and MMOS channels 
respectively. MMOS sensors require continuous airflow to operate effectively; therefore 
this pump operates whenever the instrument is switched on. The sorbent channel pump 
is operated as needed for breath sampling under software control. 
As soon as the instrument is running, the PDA may be switched on. It is important to 
check that the PDA date and time are set correctly since this information is used to 
timestamp the data. The eNostril programme may now be started (select Start ► 
eNostril). If the software cannot be found at this location, select Start ► Programs, 
then tap on the eNostril icon on the page of displayed applications. Check section 5.5 
for information on re-installing the application. 
After switching on, the Breathotron requires a minimum of 10 minutes warm-up before 
it can be used. Once this has elapsed, change to the Configure screen (Menu ► 
Configure) and ensure that the MMOS output signal lies between 0.5V and 1.5V. The 
controls on this screen are preset to optimal values and should not usually be changed 
by the operator. However, if necessary, the baseline can be adjusted using the Offset 
slider control. See below for more information on the features provided in eNostril. 
Sorbent cartridge 
The instrument is supplied with a dummy cartridge which should be replaced when it is 
not in use to avoid contamination. To remove the dummy cartridge, release the Velcro 
tie which holds it in place and lift it away from its mounting bracket. Sufficient play for 
this is allowed in the connecting tubes. Unscrew the unions at each end using a Caplok 
 5 
tool and spanner and remove the nuts. It is good practice at this point to seal the dummy 
cartridge using either permanent or temporary end caps. 
Remove the end caps from the live cartridge and fit the nuts removed from the dummy. 
Fitting the cartridge is the reversal of removal. Note that the engraved ring denotes the 
upstream end of the cartridge.  
Facemask and valve assembly 
A standard single-use anaesthetic mask is used in conjunction with a Laerdal non-
rebreathing valve (part # 560200). The flow rate sensor is connected to the output port 
of the valve. These components are all push-fit so that the mask and valve may be 
replaced as necessary. 
The mask selected should provide a snug fit around the volunteer‟s nose and mouth. For 
most applications, the mask will be held in place by a headstall. Mask adjustment 
should be checked by carrying out a positive pressure test. This is achieved by placing 
the palm of a hand over the end of the flow rate sensor and asking the volunteer to 
exhale slightly. The face seal should expand slightly against the volunteer‟s face, and 
the volunteer should not be conscious of any escaping air.  
Collecting samples 
Breath 
Go to the Setup screen in eNostril (Menu ►Setup) and complete the information fields 
(free-text) as required. 
 6 
To collect a sample, ensure that eNostril is set to the main screen (Menu ►Main; 
shown in Figure 2) and set the sample volume. The Volume control is a drop-down list 
which allows the total volume of breath to be collected to be set in increments of 500 
ml. It is recommended that a particular sample volume is specified for any given 
experimental protocol and then used exclusively. 
Tap on the Start button. The status indicator will change from Standby to MMOS 
tests: 0 and the instrument will then automatically sample alveolar breath up to the set 
volume. Progress is indicated on the thermometer bar and as the percentage of the total 
sample collected. The expiration flow rate is displayed graphically in the window at the 
top of the screen; the vertical axis is calibrated in standardised litres per minute 
(SLPM). 
Because of the long recovery time of MMOS sensors, only one breath is analysed for 
each 500ml of breath collected, the remainder passing through the sorbent tube. The 
eNostril software controls the sampling sequence such that the first sample for MMOS 
analysis is drawn after 100 ml has been collected, with subsequent samples being drawn 
 
Figure 2 eNostril main screen. The display window shows the breath flow rate in Standardised Litres 
Per Minute (SLPM). 
Status 
indicator 
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at 500 ml intervals. The number of MMOS samples is shown on the status indicator. 
The run can be terminated at any time by tapping on the Start button again. 
Note that, since sampling is controlled on the basis of volume collected, runs do not 
take a specific length of time. As a rough guide, however, allow 1 minute per 100 ml 
sample for healthy individuals sitting quietly. 
As soon as the run is complete, the volunteer may remove the mask. The sorbent tube 
should be removed from the instrument immediately and capped. Permanent caps are 
recommended. The tube should then be replaced by another live tube or the dummy; the 
tube connections should not be left open to the air for any length of time. 
Background 
Since the concentration of volatiles in breath is very low, it is essential to obtain 
samples of ambient air for comparison. An absolute minimum would be one sample for 
 
Figure 3 PDA folder structure, illustrating naming convention (folder named by date containing files 
named by time). 
 8 
each day of operation. However, we recommend taking at least two, one at the 
beginning and one at the end of each day. 
Fresh background samples are also required if the instrument is moved (e.g. into another 
room) or if there is any other marked change in ambient conditions. 
Background samples are obtained by disconnecting the sampling line from the sampling 
port and then proceeding exactly as for breath sampling. Set the same volume for breath 
and background samples. 
MMOS data 
The Breathotron stores its MMOS data as text files on the PDA which are suitable for 
emailing as attachments or for import into spreadsheet programmes such as Excel. 
These files also hold other information including the breath flow rate, sample volume 
and software settings. They are held on a removable memory card if one is fitted, or in 
the PDA‟s main memory if not. In the later case, however, data will be lost if the PDA 
battery becomes discharged. 
A sample volume of 500ml will produce a file of around 150kB. Although not large, 
they cannot reliably be opened by the Gatesware lurking on the PDA. Files should 
therefore be copied to a PC or network disk drive as soon as practicable. 
Connect the PDA to a PC running ActiveSync and drag them across using Windows 
Explorer. Figure 3 shows the PDA folder structure. Files are named by their time of 
collection, and are arranged in folders which are named by date. We recommend that 
this structure is also used on the target drive.  
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Using eNostril 
Graphical displays 
The Main, Configure and Monitor screens all allow graphical display of data. The Main 
and Configure screens show breath flow rate and MMOS output respectively, whilst the 
Monitor screen allows either of these to be selected. The vertical axes of these displays 
may be zoomed by tapping on the display at the lower and upper values to be expanded. 
The display will then be rescaled to cover this range. Successive expansions can be 
obtained by repeating this process. 
The display can be reset by tapping the “U” (Unzoom) button, which steps the display 
back through the previous zoom settings. 
Replay 
The data stored in the output text file may be replayed by eNostril in real time. The file 
to be replayed must first be copied from the secure data card to the My Documents 
folder using File Explorer: this requirement is a limitation of the PDA software.  
1. Start ► File Explorer. 
2. From the dropdown folder list Select My Device ►SD card ►eNostril. 
3. Then select folder from the relevant date and then the file to be copied. 
4. Press (tap & hold) on the file and select Copy from the pop-up menu. 
5. Navigate to My Documents, select Edit ► Paste. 
6. Close File Explorer. 
7. Start eNostril and select Replay, then select file to be replayed. 
Data are displayed as for actual sampling. Additionally, it is possible to switch freely 
between the Main, Monitor and Configure screens and between sensor and breath 
display on the Monitor screen. This feature is especially useful for examination of the 
MMOS sensor output. 
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Configure screen 
This screen (Figure 4) includes a number of controls which allow the instrument to be 
manually controlled. 
1. Peltier. This controls the temperature of the air or breath which is passing across 
the MMOS sensor. The chamber in which the sensor is mounted is heated or 
cooled as required using a Peltier device. 
2. Offset. Determines the offset of the MMOS signal amplifier. At the 
concentrations of volatiles found in breath, the sensor signal takes the form of a 
few millivolts superimposed upon a much larger baseline. Subtracting the 
baseline is the only practical way in which a usefully large amplifier gain may be 
realised. 
3. PWM. This controls the temperature of the MMOS sensor itself (which typically 
operates around 400 °C). The value actually set on this control is the duty cycle 
of the Pulse-Width Modulated signal which excites the sensor heater. 
4. Gain. This is a drop-down list which allows the gain of the MMOS signal 
amplifier to be set. The actual gain is found by multiplying the value of this 
control by 50. 
5. Pump. Checking this box turns on the pump for sorbent tube sampling. 
6. Solenoid. Checking this box opens the sampling valve, causing air or breath to be 
drawn in at the sampling port and passed through the sorbent tube. The state of 
the valve checkbox determines whether or not the sample loop becomes charged. 
 
Figure 4 eNostril Configure screen. The display window shows MMOS sensor output. See text for 
description of slider control functions. 
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7. Valve. With this box unchecked, the sample loop is placed in the sampling circuit 
so that it becomes charged with air or breath when the sampling valve is opened. 
When checked, the sample loop is placed in the MMOS circuit, so that its 
contents are flushed across the sensor. 
The Pump, Solenoid and Valve controls are also available on the Monitor screen. 
Monitor screen 
The Monitor screen (Figure 5) incorporates a graphical display which can be set to 
show either breath flow rate or the MMOS sensor signal. It also includes digital displays 
of a number of parameters such as the temperature and relative humidity inside the 
MMOS sensor chamber. These displays are all unscaled voltage readings and are not 
useful in routine operation. They are listed here for completeness (see Table 1). 
1. The Pump, Solenoid and Valve checkboxes may be used to take a sample 
manually, while monitoring the MMOS sensor signal in real time: 
2. Select Sensor on the Display drop-down. (If necessary the sensor offset may be 
adjusted on the Configure screen.) 
3. Ensure that the Solenoid and Valve checkboxes are unchecked. 
4. Check the Pump checkbox to start the sampling pump. 
5. Check the Solenoid checkbox. This causes the sample to be drawn into the 
sampling loop. 
 
Figure 5 eNostril Monitor screen. The display window can be set to show either the MMOS sensor 
output or breath flow rate. Digital channel displays show unscaled voltages. Channel assignments are 
given in Table 1 
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6. Wait at least 2 seconds for the sampling loop to fill, then uncheck the Solenoid 
and check the Valve checkbox. This switches the sampling loop into the flush 
position so that the sample is passed across the sensor. 
7. Uncheck all three boxes. 
 
Reloading the software 
The iPAQ Pocket PC device stores its application programs and data in volatile 
memory. As long as there is some charge in the battery, memory contents are retained. 
However, if the device is left unattended for several weeks, the contents of memory are 
lost as the battery becomes fully discharged. 
To overcome this problem, the software looks for a non-volatile SD Flash Memory 
Card in the iPAQ when the application is started. All Breathotron data is stored on the 
iPAQs memory card if one is detected, which retains its contents even when battery 
becomes fully discharged. If no SD Card is found, volatile iPAQ memory is used (the 
„My Documents‟ folder), and data saved here should be backed up to a PC using 
ActiveSync as soon as possible. 
When no battery power is present, the application program may also be lost, and will 
then need re-installing. The complete package of Breathotron application software is 
Channel 
number 
 
Channel 
number 
 
1 MMOS signal 5 Chamber temperature 
2 Breath flow rate 6 Not used 
3 Sampling flow rate 7 Chamber relative humidity 
4 MMOS chamber flow rate (MFC) 8 MMOS chamber flow rate 
Table 1 Breathotron analogue channel assignments. 
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distributed in one file called “BreathlMain_PPC.ARM.CAB”, which can be found on 
the supplied CD. This file should be transferred to a folder on the iPAQ file using 
ActiveSync – any folder will do. Using the iPAQ stylus and screen search for the file 
just downloaded and tap on it. This will cause the application to be automatically 
installed, then delete the original .CAB file from the local iPAQ folder. A warning 
about version compatibility may appear, but this can be safely ignored as the software 
has been configured to run of all versions of the Pocket PC operating system. 
 
 
 
 
